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ABSTRACT
Malaria is a major health problem, mainly in developing countries, and causes an
estimated 1 million deaths per year. Plasmodium falciparum is the major type of
human malaria parasite, and causes the most infections and deaths. Malaria drugs, like
any other drugs, suffer from possible side effects and the potential for emergence of
resistance. Chloroquine, which was a very effective drug, has been used since about
1945, but its use is severely limited by resistance, even though it has mild side effects,
and is otherwise very efficacious. Research has shown that there are chloroquine
reversal agents, molecules that can reinstate antimalarial activity of chloroquine and
chloroquine-like drugs; many such reversal agents are composed of two aromatic
groups linked to a hydrogen bond acceptor several bonds away. By linking a
chloroquine-like molecule to a reversal agent-like molecule, it was hoped that a hybrid
molecule could be made with both antimalarial and reversal agent properties. In the
Peyton Lab, such hybrid “Reversed Chloroquine” molecules have been synthesized
and shown to have better antimalarial activity than chloroquine against the P.
falciparum chloroquine-sensitive strain D6, as well as the P. falciparum chloroquineresistant strains Dd2 and 7G8. The work reported in this manuscript involves
simplifying the reversal agent head group of the Reversed Chloroquine molecules, to a
single aromatic ring instead of the two rings groups described by others; this
modification retained, or even enhanced, the antimalarial activity of the parent
Reversed Chloroquine molecules. Of note was compound PL154, which had IC50
values of 0.3 nM and 0.5 nM against chloroquine-sensitive D6 and chloroquinei

resistant Dd2. Compound PL106 was made to increase water solubility (a requirement
for bioavailability) of the simplified Reversed Chloroquine molecules. Molecular
modifications inherent to PL106 were not very detrimental to the antimalarial activity,
and PL106 was found to be orally available in mice infected with P. yoelli, with an
ED50 value of about 5.5 mg/kg/d.

Varying the linker length between the quinoline ring and the protonatable nitrogen, or
between the head group and the protonatable nitrogen, did not have adverse effects on
the antimalarial activities of the simplified Reversed Chloroquine molecules, in accord
with the trends observed for the original design of Reversed Chloroquine molecules as
found from previous studies in the Peyton Lab. The simplified Reversed Chloroquine
molecules even tolerated aliphatic head groups (rather than the original design which
specified aromatic rings), showing that major modifications could be made on the
Reversed Chloroquine molecules without major loss in activity.

A bisquinoline compound, PL192, was made that contained secondary nitrogens at
position 4 of the quinoline ring (PL192 is a modification of piperaquine, a known
antimalarial drug that contains tertiary nitrogens at position 4 of the quinoline ring);
this compound was more potent than piperaquine which had an IC50 value of 0.7 nM
against CQS D6 and an IC50 of 1.5 nM against CQR Dd2, PL192 had IC50 values of
0.63 nM against chloroquine sensitive D6 and 0.02 nM against chloroquine resistant
Dd2.
ii

Finally, the mechanism of action of these simplified “Reversed Chloroquines” was
evaluated; it was found that the simplified “Reversed Chloroquines” behaved like
chloroquine in inhibiting β-hematin formation and in heme binding. However, the
simplified “Reversed Chloroquines” were found to inhibit chloroquine transport for
chloroquine resistant P. falciparum chloroquine resistance transporter expressed in
Xenopus oocytes to a lesser extant than the classical reversal agent verapamil. From
these studies it was noted that the simplified “Reversed Chloroquines” may not behave
as well as classical reversal agents would in restoring chloroquine efficacy, but they
are very potent, and so could be a major step in developing drug candidates against
malaria.
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CHAPTER 1
Introduction
Malaria Problem
Malaria is a major health problem, mainly in Sub-Saharan Africa, some parts of Asia,
and South America as shown in Figure 1.1.5;10 Malaria is caused by protozoan
parasites belonging to the genus Plasmodium.11;12 There are four major species of the
parasite that cause malaria in humans, namely P. falciparum, P. vivax, P. ovale, and P.
malaria, but a fifth parasite, P. knowlesi,13;14 is now being recognized. P. falciparum is
the most virulent kind of human malaria parsite.15 Plasmodia cause an estimated 300
million clinical infections each year, and perhaps 1 million deaths annually, primarily
in sub-Saharan Africa.16-18

Figure 1.1: World map showing malaria risk areas shaded dark.
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About 90% of the deaths occur in sub-Saharan Africa in children under the age of 5.18
In fact, in every 30 seconds a child dies of malaria in Africa.18 More than 40% of the
world’s population is in malaria risk areas.18 Malaria symptoms include development
of a fever, sore joints, vomiting, and headache.19 Malaria can develop into
convulsions, coma, and death if left untreated.19 Children who suffer from severe cases
of malaria can have learning impairments resulting from brain damage even if they
survive.20 Children who have repeated cases of malaria can develop anemia, lethargy,
and generally poor development.20 Pregnant women infected with malaria can develop
placental complications, which could lead to children with low birth weights, or even
death of the fetus, in addition to the rest of the malaria-related problems.20

The Malaria Life Cycle
The Anopheles mosquito is the vector that carries the parasite. During a human blood
meal, an infected Anopheles mosquito passes the sporozoites to the human host
(Figure 1.2). The sporozoites infect liver cells, where they mature into schizonts. The
infected liver cells then can rupture and release merozoites, which then can infect red
blood cells, where they become ring stage trophozoites. CQ is active on the ring stage
of the malaria life cycle,21 and since the simplified RCQs reported in this document
are CQ-like, they are expected to act on the ring stage as well. The trophozoites
mature into schizonts, which rupture the red blood cells, releasing merozoites. These
merozoites infect other red blood cells; the blood stage of the life cycle is responsible
for the clinical symptoms of the disease as well as death.22
2
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Figure 1.2: The malaria life cycle adapted from the CDC website.1 During a blood meal, a malariainfected mosquito injects sporozoites into the human hosta. Sporozoites infect liver cells and mature
into schizonts, which rupture the liver cells and release merozoitesb-d. After this liver stage, the
parasites undergo asexual multiplication in the erythrocytes. The merozoites infect red blood cells
(where they degrade hemoglobin as a food source) e. Trophozoites in infected erythrocytes, mature
into schizonts, the red blood cell ruptures releasing more merozoites into the blood streamg-i. Some
parasites differentiate into gametocytes. CQ and other quinoline ring system drugs are believed to
act on the blood stages of the malaria life cycle.6 The gametocytes, male (micro gametocytes) and
female (macro gametocytes) are ingested by mosquito during a blood mealk. In the mosquito's
stomach, the micro gametes enter the macro gametes creating zygotes. The zygotes in turn become
ookinetes which develop into oocystsl-m. The oocysts grow, rupture, and release sporozoites which
travel to the mosquito’s salivary glands. Injection (during a blood meal) of the sporozoitesa into a
new human host repeats the malaria life cyclea.

Some parasites of P. falciparum may mature from the ring stage to become male and
female gametocytes, which may be ingested by an Anopheles mosquito during a blood
3

meal. In the stomach of the mosquito, the male gametocytes penetrate the female
gametocytes forming zygotes. The zygotes become elongated and motile ookinetes.
The ookinetes invade the midgut wall of the mosquito where they develop into
oocysts. The oocysts grow, rupture, and release sporozoites which travel to the
mosquito’s salivary glands. The sporozoites can be passed on to a human host, thus
perpetuating the cycle. In the liver stage, P. vivax and P. ovale may also develop
hypnozoites, which remain dormant and can persist in the liver. Relapses can occur
when invasion of the red blood cells occurs, and this can take weeks, months, or even
years.1

The History of Antimalarial Drugs
Quinine was introduced in 1632 when the bark of Cinchona trees from South America
was used to treat fevers.23 Resistance to quinine was noted in 1910.24 Quinine is still in
use today, although it is not a primary drug. Primary drugs are used as a first line of
defense against malaria; usually they are given in combination with another drug to
reduce the effects of resistance. During the second world war, the Japanese invaded
Java, which was the main source of Cinchona tree plant extract that had supplied
quinine for the American soldiers.25 This resulted in massive shortages in the
antimalarial drug quinine, which in turn resulted in increased death rates for soldiers
infected with malaria. It became clear that alternative drugs were required, and so
increased research on new antimalarial drugs began.25

4

A Malaria Drug Development Program was set up, which lead to the development of
antimalarial drugs like chloroquine (CQ), amodiaquine, primaquine, proguanil, and
pyrimethamine.25

CQ was introduced in about 1945, it was discovered earlier on by the Germans,
although they abandoned its development,23 but resistance to it was reported in 1957.24
Amodiaquine was first used in 1951, but resistance was first reported in 1971.24 Both
CQ and amodiaquine still are in use today, although sparingly due to resistance.
Artemisinin and its derivatives were introduced in the 1970s, but reports of resistance
to artemisinin began to surface in 1998.26 Mefloquine was first used in 1977, but
resistance was reported in 1982.24 However, mefloquine is still in use today.
Halofantrine was used from 1988 to 1990, but discontinued due to the sometimes-fatal
cardio toxicity associated with its use.24;27

Combination drugs were introduced to limit resistance. Combination therapy relies on
the premise that the probability of development of resistance to two drugs with
independent mechanisms of action is extremely low, of the order of once every 1012
treatments.28 Sulfadoxine/pyrimethamine (Fansidar) was a combination drug
introduced in 1967, but resistance was noted in the same year it was introduced.24 This
was rather disappointing because Fansidar is cheap, practicable (only one dose is
needed because it eliminates from the body slowly), and widely used in Africa.29
Fansidar is still in use today although resistance severely limits its usefulness.
5

Atovaquone/proguanil (Malarone) was first used in 1996, but resistance to it was
reported in 2002.30 Malarone is still in use today. It can be seen that malaria has
developed resistance to most, if not all, of the drugs that have been introduced, and so
there is a need to reverse this resistance.

From this history it can be seen that several drugs are used against malaria,31-34
including those derived from the 4-substituted quinoline ring system. Examples of
drugs that fall in this class are chloroquine, amodiaquine, piperaquine, mefloquine,
and quinine, shown in Figure 1.3.

Drugs of the 4-substituted quinoline class are generally thought to act on the blood
stages of the malaria life cycle.35 7-chloro-4-aminoquinoline derivatives, including CQ
and amodiaquine, are among the most potent antimalarial drugs reported to date.36-38
CQ has been postulated to prevent the conversion of ferriprotoporphyrin IX (FP) into
an insoluble material called hemozoin, as shown in Figure 1.4.6
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Figure 1.3: Examples of the 4-substituted quinoline ring system drugs. A: quinine, having a 7methoxy functional group off the quinoline ring; B: mefloquine, which has triflouromethyl
functional groups at the 2 and 8 positions; C: amodiaquine, which has a 7-chloro functional
group; D: chloroquine, which has the 7-chloro functional group; E: piperaquine, which has two
quinoline rings; A, B, C, D, and E have aliphatic chains at the 4 position of the quinoline ring.

The release of soluble FP upon hemoglobin digestion by the parasite reaches a level
which would become toxic to the parasite if it were not sequestered into hemozoin.6 It
is also noted that CQ accumulates in the digestive vacuole (DV) of

malaria

parasites;39 this accumulation is reduced in chloroquine-resistant (CQR) strains.40 Out
of these quinoline ring system drugs, CQ emerged as the most important. CQ was safe,
effective, widely used, and inexpensive. CQ could be used to treat pregnant women
and children who account for most of the deaths associated with malaria, but P.
falciparum developed resistance to it by 1957, as mentioned above, in Southeast Asia
7

(Thai-Cambodia border) and in South America.41;42 In 1978 CQ resistance had spread
into East Africa.43 Between 1978 and 1988, reports of resistance to CQ began to
surface in all the countries of tropical Africa.43 This is important because CQR malaria
accounts for the majority of malaria associated-deaths.44

Heme

Heme dimer

Hemozoin

CQ

CQ-Heme Complex
Figure 1.4: Presumed CQ mode of action. Free heme in the parasite forms heme dimers which
mineralize into hemozoin. In the presence of CQ hemozoin formation is inhibited. CQ caps the
ends of heme dimers to form a sanguage like complex.6;7

CQ resistance is linked to a mutation in codon 76 of the P. falciparum CQR
transporter (PfCRT), resulting in a change of lysine to threonine (K76T).45 PfCRT is
located on the membrane of the DV of P. falciparum during the blood stage of the
parasite’s life cycle.46 Mutations at other positions, when in the presence of K76T, can
give rise to different strains, having different degrees of resistance. P. falciparum
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strains with the K76T point mutation accumulate less CQ in the DV, presumably
because CQ efflux from the DV is enhanced, as shown in Figure 1.5.8 It has been
noted that all clinical isolates that did not respond to CQ treatment have this point
mutation.45

Red blood cell
Hb
P. falciparum
amino acids + heme

X
X

PfCRT
CQ

DV

Hemozoin

CQ
+

RA

Figure 1.5: CQ resistance and presumed mechanism. CQ enters the parasites DV by passive
diffusion through the red blood cell and P. falciparum membranes. The pH in the DV is low
(~5), hence CQ becomes protonated and trapped in the DV. The malaria parasite digests
Hemoglobin into amino acids (used for the parasites metabolism) and free heme which is toxic
to the parasite. Heme is mineralized by the parasite to hemozoin which is not toxic to the
parasite. CQ prevents heme from mineralizing; this is lethal to the parasite. CQR strains
accumulate less CQ in the DV and this has been associated with PfCRT.8;9 RA are compounds
that reverse the CQ resistance.

Mutations in codon 86, resulting in the change of asparagine to tyrosine (N86Y) in
the P. falciparum multi-drug resistance gene (pfmdr1), have also been associated with
CQ resistance.47
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Primaquine (and other 8-aminoquinolines under development) primarily acts on the
hepatic stage of the life cycle.34;35 Examples of 8-aminoquinolines include primaquine,
tafenoquine, pamaquine, and pentaquine, and are shown in Figure 1.6. Out of these 8aminoquinolines, primaquine has been mainly used to treat patients infected with P.
vivax and P. ovale and to prevent relapses from malaria.48;49 Primaquine cannot be
prescribed to patients with glucose-6-phosphate dehydrogense (G6PD) deficiency or
pregnant women (because G6PD deficiency cannot be detected in the fetus), because it
results in hemolysis.49 The mechanism of action of primaquine is not clearly
understood; two of the modes of action that have been proposed are given below.
Primaquine is presumed to be metabolically activated in the liver to generate
metabolites which can act on parasite nucleophiles. Also, infected hepatocytes and
erythrocytes contain ferrous iron that can facilitate the generation of oxidative radical
species which act on the parasite.50 These 8-aminoquinolines have been demonstrated
by Whichard, et al. to bind to DNA, which could then inhibit DNA function, and
therefore result in their antimalalarial action.51 Howells, et al. suggested that the
resistant parasites overcome the damaging effects of 8-aminoquinolines on their
mitochondria by synthesizing more mitochondria to compensate for the functional
loss.52
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Primaquine

Pamaquine

Tafenoquine
CF3

O

O
N

N
HN

O
NH2

HN

O
N

N

O

HN

NH2

Pentaquine
O
N
HN

H
N

Figure 1.6: Examples of 8-aminoquinolines. Primaquine, tafenoquine, pamaquine, and
pentaquine.

Antifolates are another class of compounds that act against malaria. They have been
shown to inhibit the synthesis of folate cofactors selectively which are needed for
amino acid and nucleotide synthesis.53 The enzyme inhibited by these drugs is
dihydrofolate reductase.54 Sulfadoxine and pyrimethamine in combination (Fansidar)
show synergism, increasing their effectiveness against P. falciparum.22 Examples of
antifolates are shown in Figure 1.7.
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Figure 1.7: Examples of antifolates. Sulfadoxine, pyrimethamine, and proguanil.

Point mutations at the dihydrofolate reductase (dhfr) codon 108, which result in a
change of serine to asparagine (S108N), are linked to pyrimethamine resistance, while
a change of serine to threonine (S108T) along with a change in alanine to valine
(A16V), is associated with resistance to cycloproguanil and chloroproguanil.47
Mutations have also been found which are associated with sulfadoxine resistance in
dihydropteroate synthase (dhps) genes on codons 436, 437, 540, and 581.55;56
Mutations in both dhfr and dhps both affect their catalytic functions in folate
biosynthesis.

Artemisinin and two of its most important derivatives are shown in Figure 1.8.
Artemisinin is water insoluble, thus not very bioavailable; hence the derivatives
artesunate and artemether were synthesized to increase water solubility and
bioavailability.57 These compounds have a wide spectrum of activity, including being
effective against the ring stage of the parasite.58 Artemisinins may also suppress
12

gametocyte transmission.58;59 Artemisinins accumulate in the P. falciparum-infected
red blood cells, and are thought to kill the parasite via the action of free radicals
generated by the action of ferrous iron or exogenous free iron.60

Figure 1.8: Examples of the artemisinin group of compounds. Artemisinin, artesunate, which
has a carboxylic acid side chain, and artemether, having a methoxy side chain.

Although artemisinin has been quite effective in the fight against malaria, there are
reports on artemisinin resistance due to a change in serine to asparagine (S769N) on
the sarco/endoplasmic reticulum calcium-dependant ATPase (SERCA; PfATPase6 )
gene.61 However, others have shown doubts on artemisinin even inhibiting SERCA;
PfATPase6.62

These are the main groups of drugs in use today, although other drugs like
doxycycline are still used in different parts of developing countries.63;64
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Other Motivations for Continued Development of New Antimalarial Drugs
A number of different side effects have been linked to antimalarial drugs. For
example, Malarone is associated with abdominal pain, nausea, vomiting, and
headaches. Malarone is not safe for pregnant women, nor children weighing less than
25 pounds.19 Mefloquine-induced side effects include headaches, nausea, dizziness,
CNS-associated vivid dreams, and anxiety.19 The side effects associated with
artemisinin combination therapies include mild gastralgia, vomiting, dizziness, and
asthenia.65 These side effects have, in turn, resulted in the erratic use of antimalarial
drugs, which then fuels the progression of antimalarial drug resistance.66

The high cost of many of the more effective drugs, relative to the ability of the
endemic market’s ability to pay, is another factor that leads to erratic antimalarial drug
use. Detailed research on malaria drugs has often been limited, and as a result
prescribers are not in a position to give a detailed explanation of drug usage as well as
side effects.66 There is a continued need for the development of newer drugs as a result
of resistance, side effects, and the cost of many of the current drugs on the market.
CQ, with its few side-effects, safety, and low cost is a regrettable loss. In fact, CQ is
still being used, although it often fails due to CQ resistance. It would be good if there
were a way to re-introduce CQ or something very much like it, as an effective drug.

14

Reversal Agents
Reversal agents (RAs) are compounds that are known to reverse CQ resistance. RAs
in the presence of CQ, can reinstate the antimalarial activity of CQ in CQR strains of
P. falciparum. RAs help prevent the export of CQ from the DV as shown in Figure
1.5, so that CQ can exert its antimalarial action in the DV.

Figure 1.9: Examples of reversal agents. They all have 2 phenyl head groups linked via an
aliphatic chain to a hydrogen bond acceptor (generally nitrogen, shown in bold in the
drawings).

Verapamil (Figure 1.9) was discovered to reverse CQ resistance,67 and in due course
certain tricyclic antidepressants68 and antihistamines69 were also been shown to
15

reverse CQ resistance; these compounds are termed chemosensitizers, or RAs.
Examples of RAs shown to overcome antimalarial resistance are shown in Figure 1.9.

A three-dimensional QSAR pharmacophore model for CQR reversal was developed
from imipramine, desipramine, and 15 of their analogues.2 The pharmacophore was
constructed from two aromatic hydrophobic interaction sites linked by an aliphatic
chain to a hydrogen bond acceptor site (generally nitrogen)2 as shown in Figure 1.10.

Hydrophobic portion

Hydrogen bond acceptor
Figure 1.10: The RA pharmacophore as proposed by Bhattacharjee and his group is two
aromatic rings linked via an aliphatic chain to a hydrogen bond acceptor (generally nitrogen).
Note that the RA shown in this diagram in imipramine

Initial Work on Reversed Chloroquines (RCQs)
In the Peyton Laboratory (Portland, Oregon), it was postulated that by linking a RAlike moiety to a CQ-like moiety, it would be possible to create a class of hybrid
molecules that have antimalarial properties and can overcome resistance as well.4
16

Others, have modified CQ and created new compounds with improved activity to
CQR strains of P. falciparum.70-74 One advantage of these hybrid molecules is that, in
principle, it might be administered at a lower dose than the RA component of a
cocktail. Proteins involved in drug efflux in the DV of the malaria P. falciparum
parasite may also fail even to recognize this hybrid molecule and thus fail to export the
drug, rendering the drug active in the DV. Reducing the dose could make the hybrid
drug cheaper and reduce the side effects, including toxicity that may be associated
with administering two separate drugs. Figure 1.11 shows PL01, the first such
molecule, which was synthesized by Steven Burgess in the Peyton Laboratory.4

CQ like portion

Reversal agent like portion

Figure 1.11: The hybrid molecule PL01. The first molecule synthesized in the Peyton lab that
is composed of a link between a CQ like portion and a RA like portion (i.e. an imipramine like
portion).
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The postulated hybrid molecule approach was demonstrated to be viable, as shown by
the results in Table 1.1. The hybrid compound PL01 was potent against both CQS and
CQR strains of P. falciparum. In fact, PL01 had better activity than CQ for both CQS
and CQR strains of P. falciparum.4 PL06 (Figure 1.12) was subsequently made by
Steven Burgess in the Peyton Lab. PL06 is a modification of PL01 that deleted the
center ring of the tricyclic group of the “tricyclic antidepressant” imipramine RA;
however it retains the antimalarial activity of PL01.75

Table 1.1: IC50 values of the previous compounds made in the Peyton
Lab.4 The values of CQ have been included for comparison. There is a
30% uncertainty in the IC50 values that may result from differences in
weighing and/or variations in determining IC50.
IC50 value in nM
Compound
Structure
D6
Dd2

CQ

6.9

102

PL01

2.9

5.3

PL06

2.4

3.7

It was thus decided to alter the RA head group and so deviate further from the RA
pharmacophore proposed by Bhattacharjee, et al.,2 which stated that there was need
for two aromatic rings and a hydrogen bond acceptor several bonds away.
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Hydrophobic portion

Hydrogen bond acceptor

PL06

Figure 1.12: PL06 a modification of PL01, this diagram shows how PL06 fits the
pharmacophore proposed by Bhattarcharjee, et al.2

The next Chapter introduces work that was done to further simplify the RCQs.
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CHAPTER 2

The Approach

In the first Chapter, the idea of RCQs was introduced. In the work presented here, the
RA is more drastically changed from the RA pharmacophore described by
Bhattacharjee, et al.,2 in order to obtain an expanded structure activity relationship
(SAR) of the RCQs. Initially, PL112 was made which contained a biphenyl ring
system shown in Figure 2.1 instead of the branched pair of aromatic rings proposed by
Bhatacharjee, et al..2 From PL112 we can see that the hydrogen bond acceptor of the
pharmacophore has been maintained but the hydrophobic portions have been
significantly altered; instead a biphenyl group is presented in place of the branched
aromatic rings that are described in the pharmacophore by Bhattacharjee, et al..2

HN

Hydrophobic portion

N
N

Cl

N
Hydrogen bond acceptor

Figure 2.1: PL112 the first compound synthesized with a variation in the RA head group to a
biphenyl group.
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PL112 and most of the compounds mentioned in this thesis were made via Scheme
2.1. First, 4,7-dichloroquinoline was treated with excess 3-aminopropan-1-ol to make
PL16. Next, PL16 was treated with methanesulphonylchloride to make PL29.4 PL29
was then used as a starting material for addition of the piperazine analogues to make
PL112 and most of the compounds mentioned in this thesis.

Despite these alterations to the RA portion of the RCQs, it was noted that PL112 had
good antimalarial activity (Table 2.1). This was a surprising improvement to the
activity of PL06, and so further variations in the head group were made, specifically
altering the arrangement of the RA phenyl groups from meta, to ortho, and then to the
para position as shown in Figure 2.2.
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Figure 2.2: Initial compounds synthesized with a biphenyl head group with variations from
the ortho, to meta, then to the para position.

This initial group of compounds was designed as an enquiry as to how far the RA head
group could be perturbed with retention of antimalarial activity. These results are
shown in Table 2.1, and demonstrate that having a biphenyl head group enhances the
activity of the compounds slightly. PL110 which has a linear arrangement of the
phenyl groups has increasingly lower IC50 values than the other compounds in the
series, with IC50 values of 0.7 nM and 0.6 nM for CQS D6 and CQR Dd2,
respectively. These results were surprising because the linear head groups appear to
deviate from the branched phenyl groups pharmacophore described by Bhattacharjee,

et al..2
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Table 2.1: Biphenyl ring system compounds. The values of CQ, PL01,
and PL06 have been included for comparison. There is a 30% uncertainty
in the IC50 values that may result from differences in weighing and/or
variations in determining IC50 (See Chapter 7).
IC50 value in nM
Compound
Structure
D6
Dd2

CQ

6.9

102

PL01

2.9

5.3

PL06

2.4

3.7

PL112

1.2

2.6

PL111

0.9

1.8

PL110

0.7

0.6
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These results are a clue that a simple model of CQ linked to the RA pharmacophore is
not the full explanation of how more potent IC50 values may be obtained for the
RCQs. Figure 2.3 shows a graphical representation of the activities of the biphenyl
ring system compounds.

14

102

12

IC 50 (nM)

10
8

D6
Dd2

6
4
2
0
CQ

PL01

PL06

PL112

PL111

PL110

Compound

Figure 2.3: Activity of biphenyl ring system compounds PL112, PL111, and PL110. CQ, PL01, and
PL06 have been included for comparison. There is a 30% uncertainty in the activities of the
compounds that results from weighing and obtaining IC50 values. The white bars are for CQS strain
D6 and the grey bars are for CQR strain Dd2.

Single Phenyl Head Group

From the results above, it was hypothesized that one of the phenyl groups could be
removed without substantial loss of antimalarial activity, as illustrated in Figure 2.4.
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Figure 2.4: Transition from biphenyl head group to single phenyl head group.

A set of compounds with a single phenyl head group (the aromatic portion of the RA)
was synthesized as outlined in Scheme 2.1. PL91 had surprisingly low IC50 values of
0.5 nM for both CQS D6 and CQR Dd2 of P. falciparum. This result was surprising
because the head group is just a single aromatic group instead of the branched
aromatic head groups defined by the pharmacophore. Due to this success, more
compounds were made to further investigate an expanded SAR of the single head
group. Initially, compounds with electron withdrawing groups on the phenyl group
shown in Table 2.2 were synthesized. PL154 gave quite impressive IC50 values of 0.3
nM for CQS D6 and 0.5 nM for CQR Dd2. PL154 and PL156 were made to test the
effect of having halogens as electron withdrawing groups. From these two compounds,
it can be seen that interchanging the halogens (fluorine and chlorine) does not strongly
affect the activity of the compounds. PL155 was made to test the effect of having two
electron withdrawing groups on the RA aromatic head group. This change also does
not strongly affect the activity of these compounds. PL159 has an additional oxygen
group that generally increases water solubility as well as has electron withdrawing
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properties. PL159 has hydrogen bonding potential which may have had some
detrimental effects on its antimalarial activity.

Table 2.2: Single aromatic head group and electron withdrawing groups.
The values of CQ have been included for comparison. There is a 30%
uncertainty in the IC50 values that may result from differences in weighing
and/or variations in determining IC50 (See Chapter 7).
IC50 value in nM
Compound
Structure
D6
Dd2

CQ

PL91

PL154

PL155

PL156

PL158

PL159

6.9

102

0.5

0.5

0.3

0.5

0.9

0.7

2.0

0.2

0.06

0.2

4.1

4.1

0.9

0.8

PL257

The electron withdrawing groups did not result in large changes in the activities most
of the simplified RCQs, although PL159 has a slight loss in antimalarial activity.
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PL158 and PL257 had stronger electron withdrawing groups, which seemed not to
reduce the activity of the compounds. It was thus noted that these changes in the
electron withdrawing groups on the phenyl group were well tolerated. This is an
important factor in these antimalarial compounds, because if mutations arise in the
parasite, new substitutions can be made easily without loss of activity. Also, if the
compounds are found to perturb certain biological functions in the body (i.e., cause
toxicity and/or side-effects), alterations in the compounds can be made without major
deleterious effects on the antimalarial activity of the compounds. Figure 2.5 shows a
graphical representation of the activities of the single aromatic head group
compounds.

14

102

12

IC50 (nM)

10
8

D6

6

Dd2

4
2
0
CQ

PL91

PL154

PL155

PL156

PL158

PL159

PL257

Compound

Figure 2.5: Single aromatic head group and electron withdrawing groups. The values of CQ
have been included for comparison. There is a 30% uncertainty in the IC50 values that may
result from differences in weighing and/or variations in determining IC50. The white bars are
for CQS strain D6 and the grey bars are for CQR strain Dd2.
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Better Solubility

Lipinski’s rules suggest that bioavailable small compounds generally have a ClogP
value of <5.76 In this document, ClogP is a calculated value for an organic compound
given by Chemdraw Ultra 12.0 that estimates the distribution of a compound between

n-octanol and water. In essence it is a measure of how water soluble or hydrophilic a
compound is. The compounds synthesized this far, had on average, very good
activities, but the ClogP values were greater than 5, suggesting that they were rather
hydrophobic, and hence may be less bioavailable than desired. The initial set of
compounds was found to be insoluble in water; chloride salts of these compounds
were made which were equally insoluble. The salts were prepared by dissolving the
compound in methanol, and then adding excess methanolic acid at less than 0oC.
Finally the solvent was evaporated off to get the salts. The next set of compounds that
were synthesized had ClogP values of less than 5. The compounds were synthesized as
outlined in Scheme 2.1. The lower ClogP values were achieved by substituting some
of the carbon atoms in the compound with nitrogens. These new compounds (Table
2.3 and Figure 2.6), as free bases, were insoluble in water as well; however their
chloride salts were soluble in water.
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Table 2.3: Compounds with Clog P values <5. The values of CQ and PL01 have
been included for comparison. There is a 30% uncertainty in the IC50 values that
may result from differences in weighing and/or variations in determining IC50 (See
Chapter 7).
IC50 value in nM
Compound
Structure
ClogP
D6
Dd2
6.5

102

PL01

2.9

5.3

PL112

1.2

2.6

0.5

0.5

5.8

0.3

0.5

6.6

2.7

1.8

4.3

0.5

1.6

4.3

1.4

2.3

4.1

CQ

PL91

PL154
HN

N

N
N

PL106
Cl

5.1

8.9

7.7

N

PL109

PL261
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Despite these atomic alterations, and resultant change in ClogP value, PL106 was
potent to within an order of magnitude as PL91, the analogous compound, with IC50
values of 2.7 nM and 1.8 nM for CQS D6 and CQR Dd2. PL109 (Table 2.3) shows
that moving the nitrogen in the pyridine ring from the ortho to the para position does
not adversely affect the activity of the PL106. PL261 was synthesized to increase
solubility further. This compound tolerated the addition of another nitrogen group in
that the activity of the compound did not change by a great margin.

12

102

10
8
CQS
CQR

IC50 (nM) 6

ClogP
4
2
0
CQ

PL01

PL112

PL154

PL106

PL109

PL161

Compound

Figure 2.6: Compounds with Clog P values <5. The values of CQ and PL01 have been
included for comparison. There is a 30% uncertainty in the IC50 values that may result from
differences in weighing and/or variations in determining IC50 (See Chapter 7). The white bars
are for CQS strain D6 and the grey bars are for CQR strain Dd2, the bars with the diagonal
lines show the ClogP values of these compounds; please note that ClogP values lack units.

Toxicity is another hurdle that any drug development program needs to overcome.
PL106 and PL261 have superior cytotoxicities of 13 300 and 28 000 respectively
against human hepatic cancer cells. These compounds (PL106 and PL261) have high
antimalarial potency and yet very low toxicity, for a “therapeutic index”
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(cytotoxicity/efficacy) of 4 900 for PL106 D6 and 7 300 for PL106 Dd2; for PL261
the “therapeutic index” is 20 000 for D6 and 12 100 for Dd2. These values are far
better than our calculated “therapeutic index” values for CQ: 1 700 for D6 and only
120 for Dd2 and thus show that these compounds could be potential drug candidates.

In vivo Studies
In vivo tests were done, to test for bioavailability of the compounds as well as possible
signs of toxicity. PL106 was tested at the Swiss Tropical and Public Health Institute
(Basel, Switzerland) by Sergio Wittlin and Reto Brun, in mice infected with P.

berghei, and cured 1 out of 3 mice at a dose of 30 mg/kg/d in a 30-day trial, as shown
in Table 2.4. Detection of parasitemia was done on day 4, and it was noted that the
control mice had 63 580 parasitized red blood cells (RBCs), while the mice dosed with
PL106 had no detectable parasitized RBCs on day 4. It is expected that at a higher
dosage, all of the mice may be cured of malaria. Also, PL106 may be administered in
combination with another drug that may clear the remaining parasites. These results
were very encouraging, and lead us to do more in vivo studies as shown below. P.

falciparum is very specific to the human host, hence mouse models of P. falciparum
are not generally viable.77 However, work has been done to express the different
stages of the P. falciparum life cycle in mice, so that in the future it is hoped that the
complete life cycle of P. falciparum can be expressed in a single mouse.77
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Table 2.4: In vivo mouse studies with P. berghei. PL106 was
administered at 30 mg/kg/d for 4 days. Parasetemia was determined
on the 4th day. 0 represents undetectable levels of parasetemia.

Test

Parasitized RBC

Mouse survival in days

Control 1

635 80

4

0

14

0

16

0

30

PL106,
mouse 1
PL106,
mouse 2
PL106,
mouse 3

Tests on P. yoelii have been done by Marty Smilktein, at the Oregon Translational
Research and Drug Development Institute (OTRADI, Portland, Oregon) to test further
the mouse efficacy of some selected compounds. Results for these tests are shown in
Table 2.5. For these experiments CF-1 out-bred mice were infected with P. yoelli.
Forty mice were injected intravenously through the tail vein with 5 X 105 infected
RBCs. The mice were placed in groups of 4 with a water control, in order to evaluate
PL154, PL157, PL106, and PL261. The mice were dosed at 1, 4, 16, 64 mg/kg/d with
the simplified RCQ salts and weighed daily. Treatments were administered once daily
X 3, then 24 hours after the final dose, blood smears were made and parasetemia
determination by counting by light microscopy. Compounds PL106 and PL261 were
found to be orally available, with ED50 values of 5.5 and 6.0 mg/Kg/d respectively.
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Table 2.5: In vivo mouse tests
with P. yoelii.
Compound
PL154
PL157
PL106
PL261

ED50 (mg/Kg/d)
<<15
<<15
5.5
6.0

Short toxicity studies were also carried out on the mice. One mouse received 500 mg/
kg/d X 2 days, and another mouse received 500 mg/kg/d X 1 of PL157. Both mice had
previously been infected with P. yoelii 2-3 days before dosing. The maximum weight
loss was ~10%, and this weight loss leveled off after dosing stopped, suggesting
absence of ongoing toxicity. The only visible effect that was noted was minimal
lethargy 1 hour after the highest dosing which may have reflected the large volume
(0.5 mL) required for this high dose. From these results it was noted that 500 mg/kg of
PL157 was well tolerated, hence the compounds were not toxic according to the
experiment.

Summary of the Approach

From these results, it is possible to introduce the biphenyl head group to the RCQs and
still maintain antimalarial activity. Modifications that result in a single phenyl group
were also well tolerated by these compounds, and it was noted that electron
withdrawing groups resulted in compounds with increased potency. However, these
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compounds were rather water insoluble and so pyrimidine and pyridine head groups
were introduced to increase solubility. This change did not adversely affect the
antimalarial activities of the simplified RCQ compounds. From the in vivo mouse
studies, it can be seen that PL106 is a viable drug candidate because it was orally
available. Figure 2.7 shows a graph of in vitro potencies of all the compounds
presented in this chapter. From this graph we see that the compounds all have
activities lower than CQ against either CQS or CQR P. falciparum strains D6 and Dd2
respectively, showing that modifications on the head group can be made without loss
of activity.
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Figure 2.7: IC50 values for CQ and synthesized PL compounds. The white bars are for CQS
D6 strain and the grey bars are for the CQR Dd2 strain, of P. falciparum malaria.
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CHAPTER 3

Assessing the Boundaries for the Simplified RCQs Pharmacophore

Aliphatic Head Group

In the previous chapter, simplified RCQs with good bioavalability and high activity
were introduced. In the work presented here, compounds were synthesized to assess
the boundaries of the RCQ pharmacophore. Initially, compounds were made to test
whether having an aliphatic, rather than an aromatic, head group would be detrimental
to the antimalarial activity of the compounds. Bhattacharjee, et al. proposed that RAs
contain aromatic head groups, so having aliphatic head groups is a major deviation
from the proposed pharmacophore, as shown in Figure 3.1

Figure 3.1: PL229: A compound with an aliphatic head group instead of the aromatic head
group proposed by Bhattacharjee, et al.

In the Peyton Lab an RCQ having an adamantane head group has been synthesized by
Steven Burgess and shown to have antimalarial activity of < 2nM for both CQS D6
and CQR Dd2 P. falciparum strains of malaria. Table 3.1 shows the antimalarial
results for the aliphatic head group compounds that were synthesized for this study.
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These compounds were synthesized as outlined in Scheme 2.1. PL228 was synthesized
to test the addition of a methylene group between the piperazine ring and the now
aliphatic head group. Surprisingly, PL228 and PL229 had IC50 values within the same
order of magnitude with the other simplified RCQs. This further verified the fact that
even major variations in the head group do not negatively affect the activity of these
compounds.

Table 3.1: Antimalarial activity of compounds with aliphatic head
groups. The values of CQ and PL91 have been included for comparison.
There is a 30% uncertainty in the IC50 values that may result from
differences in weighing and/or variations in determining IC50 (See
Chapter 7).
IC50 value in nM
Compound
Structure
D6
Dd2

CQ

PL91

6.9

102

0.5

0.5

1.0

2.0

0.2

0.4

PL229

PL228

Linker Length
Previous work in the Peyton Lab78 has shown that varying the linker length between
the quinoline ring and the protonatable nitrogen, or between the protonatable nitrogen
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and the head group, does not have adverse effects on the antimalarial activities of
these compounds. This finding was tested with the simplified RCQs. PL274 was made
as outlined in Scheme 2.1, although 3-aminopropan-1-ol was substituted by 2aminoethan-1-ol. PL227 was synthesized as outlined in Scheme 2.1, and DM1020 was
obtained from Steven Burgess of DesignMedix (Portland, OR). Table 3.2 and Figure
3.2 show the results for this antimalarial testing. It can be seen that varying the linker
length does not strongly and adversely reduce the antimalarial activity of the
compounds, in accord with previous results on other compounds in the Peyton Lab.78

Table 3.2: Compounds with variable linker lengths. The values of CQ have
been included for comparison. There is a 30% uncertainty in the IC50 values
that may result from differences in weighing and/or variations in determining
IC50 (See Chapter 7).
IC50 value in nM
Compound
Structure
D6
Dd2

CQ

PL274

PL91

DM1020

PL227
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Figure 3.2: Compounds with variable linker lengths. The values of CQ have been included for
comparison. There is a 30% uncertainty in the IC50 values that may result from differences in
weighing and/or variations in determining IC50 (See Chapter 7).

PL163 and PL157 (shown in Figure 3.3) were synthesized as outlined in Scheme 2.1,
and PL163 has a methyl head group, which has mild electron donating properties,
while PL157 has electron donating properties provided by the methoxy functional
group. These modifications did not seem to have a major impact on the activity of the
compounds. PL163 had IC50 values of 0.1 and 1.3 nM for CQS D6 and CQR Dd2
respectively. While PL157 had IC50 values of 1.3 and 0.3 nM, for CQS D6 and CQR
Dd2 respectively.
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Figure 3.3: PL163 and PL157 with electron donating groups on the head group.

PL223, shown in Figure 3.4, was made with a naphthyl head group. This compound
has a head group that somewhat mimics the quinoline ring. Despite this modification,
there was no major change in activity from PL91. PL223 had IC50 values of 1.1 nM
for both CQS D6 and CQR Dd2. Synthesis of this compound was as outlined in
Scheme 2.1.

HN

N
N

Cl

N

PL223

IC50: 1.1D6, Dd2

Figure 3.4: PL223 a compound with a naphthyl head group.

Compound 5b and 5c made by Fattorusso, et al.,5 shown in Figure 3.5 are somewhat
similar to PL106 and PL109, however, there are differences in the linkers between the
pyridine rings and the quinoline rings. These differences seem to result in more potent
compounds for PL106 and PL109 though the Plasmodia species tested were different.
The higher activities of PL106 and PL109 maybe because these compounds resemble
CQ, and also the head group and the quinoline ring of these compounds are behaving
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like a RA. This is different in 5b and 5c which have a shorter chain towards the
protonatable nitrogen which is shown in bold. Bhattacharjee, et al. proposed that the
protonatable nitrogen is a few bonds away from the hydrophobic groups.2

Figure 3.5: Compounds 5b and 5c made by Fattorusso, et al.,5 in comparison with the
simplified RCQs PL106 and PL109. D10 is a CQS strain of P. falciparum, while W2 is a CQR
strain of P. falciparum. The bold nitrogen atoms are protonatable and resemble the
pharmacophore proposed by Bhattacharjee, et al.
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CHAPTER 4
Inverse Piperaquine

In this chapter, the focus is on the synthesis of compounds that contain two quinoline
rings. Piperaquine (see Figure 4.1) replaced CQ as a first line drug in China from its
introduction in 1970 until reports of emergence of resistance in 1990.79 The
Vennerstrom group has investigated the antimalarial effects of a number
bisquinolines; one example of such a compound is shown in Figure 4.1.3 These
bisquinolines have been shown to be potent against malaria. For example, piperaquine
had an IC50 value of 0.7 nM against CQS D6 and an IC50 of 1.5 nM against Dd2.

Figure 4.1: Piperaquine a known antimalarial drug. B is a bisquinoline synthesized by the
Vennerstrom group.3

Although most CQ-like drugs have a 2o amine at the quinoline 4-position, piperaquine
is an exception, having a 3o amine at this position. Having a 3o amine at the quinoline
4-position of piperaquine has been pointed out as detrimental by others.80 In the
Peyton Lab, PL02 and PL135 have been synthesized and these compounds are shown
in Figure 4.2. From these two compounds it was observed that a 2o nitrogen on the 4position of the quinoline ring results in a more potent compound, than if it were a 3o
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nitrogen. For PL02, which has the 2o nitrogen at position 4 of the quinoline ring, the
IC50 value for D6 was 1.0 nM for Dd2, and 3.6 nM against Dd2, as compared to 22
nM for D6 and 114 nM for Dd2 for PL135, which has a 3o nitrogen at position 4 of the
quinoline ring.

o

Figure 4.2: PL02 with a 2 nitrogen on the 4 position of the quinoline ring. PL135 has a 3
nitrogen on the 4 position of the quinoline ring. Note that the IC50 values are in nM.

o

In the Peyton Lab, work has been done by Simeon Andrews to evaluate the
implications of having a piperazine ring on the 4 position of the quinoline ring.78 Both
compounds, PL38 and PL51 shown in Figure 4.3 have reduced antimalarial activities
than their analogues PL50 and PL52 shown in Figure 4.3. The activity loss in PL38
and PL51 was postulated to be due to the lack of a 2o nitrogen at position 4 of the
quinoline ring.78
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Figure 4.3: PL51 and PL38: compounds with piperazine rings α to the quinoline ring; PL52
and PL50: compounds lacking the piperazine rings. Note that the IC50 values are in nM.

Due to these findings, bisquinoline ring system compounds PL192 and PL255 (Figure
4.4) were synthesized. These bisquinoline compounds were expected to have better
activity than piperaquine because of the 2o nitrogens on the 4-position of the quinoline
ring. Also, the compounds were expected to be more potent because one of the
quinoline rings might be acting as a RA, while the other quinoline ring would exert its
antimalarial activity. These compounds were synthesized as shown in Scheme 4.1.
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Figure 4.4: Bisquinolines. PL192 and PL255 have the piperazine group in the middle of the
compound and hence they have 2o nitrogens at position 4 of the quinoline ring. Piperaquine and
PL174 have piperazine rings on the 4-position of the quinoline ring, hence they have 3o nitrogens
at position 4 of the quinoline ring.

PL255 was synthesized to show the importance of the 7-chloro group for the
bisquinolines. Work done in the Peyton lab has shown that that removing the 7-chloro
group for the RCQs is not very detrimental, in contrast to CQ losing the 7-chloro
group, as shown in Figure 4.5.75
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Figure 4.5: Effect of losing the 7-chloro group on CQ and the P.L compounds.

The compounds in Figure 4.3 were made by treating 4,7-dichloroquinoline or 7chloroquinoline with 1,4-bis(3-aminopropyl)-piperazine, in phenol as reaction solvent
as shown in Scheme 4.1. The suspension was heated at 190oC for 4 hrs. The mixture
was allowed to cool and then the bisquinoline was extracted with aqueous sodium
hydroxide followed by chloroform.

PL192 had an IC50 value for D6 of 0.63 nM, for Dd2 it was 0.02 nM compared to 4.9
45

nM for D6 and 9.8 nM for Dd2 for PL255. This result shows that the 7-chloro group is
somewhat important for activity, although not to the same order of magnitude as
reported in the Peyton Lab for CQ (Figure 4.4).75 PL192 was found to be more potent
than piperaquine as predicted; this may have been due to the presence of 2o nitrogens
at position 4 of the quinoline rings. However, piperaquine and PL174 have activities
within the same order of magnitude, showing that removing the chlorine on position 7
of the quinoline ring was not very detrimental. In contrast PL192 and PL255 have a
difference in activity that is about 1 order of magnitude, indicating that losing the
chlorine on position 7 of the quinoline ring was detrimental to the activities of these
compounds as shown in Figure 4.4.
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CHAPTER 5
Mode of Action Studies
Missing Quinoline Ring

The previous chapters focused on the antimalarial activities of the simplified RCQs.
However, it is important to understand the mechanism(s) by which these compounds
work. In this chapter, a more focused investigation of the mechanism of action of
these compounds is presented. Compounds PL272, PL260, and PL273 shown in
Figure 5.1 were made that lacked the quinoline ring, to assess the possibility of any
residual antimalarial activity of the rest of the molecules. The simplified RCQs
presented in the earlier chapters were surprisingly potent, and it was hypothesized, that
the RCQ head groups may have potential RA activity. PL272 lacks the quinoline ring,
the amide is presumed to prevent the nitrogen from being protonatable just like in the
parent RCQ compounds.
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Figure 5.1: Variations of the head group. These compounds will test the reversal agent activity
of the head group. PL243 is just the piperazine head group. PL272 has the aliphatic chain
linked to the piperazine ring. PL273 has pyridine ring attached to the head group. PL260
contains a head group attached to a benzene ring.

In the Peyton lab, PL74 (Figure 5.2) has been made, and it had an IC50 of 185 nM
against D6 and 169 nM against Dd2. This result itself was rather surprisingly good;
there was activity in this compound despite the missing quinoline ring. As a result,
PL273 was made and had IC50 values of >2500 nM for both CQS D6 and CQR Dd2.
PL273 was less potent than PL74, perhaps because it lacked the biphenyl head group
which may be involved in pi bonding with free heme. This was an indication that the
simplified RCQs may have a different mode instead of action instead of, or in addition
to the unsimplified RCQs.
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Figure 5.2: PL74, having a pyridine group in place of the quinoline ring.

PL272 had activities of >2500 nM for both CQS and CQR strains of P. falciparum.
PL243 and PL260 were also tested and showed no detectable antimalarial activity up
to 2500 nM. This result clearly shows that the simplified RCQ head group does not
have significant intrinsic antimalarial activity. PL272 was made via Scheme 5.1.
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First the piperazine analogue was treated with N-(3-bromopropyl) phthalimide in
chloroform with triethylamine as base. The formed product was treated with hydrazine
in ethanol to form the amine. The amine was then treated with acetyl chloride in
acetonitrile with triethylamine as base to form PL272.

PL273 was synthesized via Scheme 5.2 by treating the 4-chloropyridine with 3chloropropionyl chloride in DCM. The synthesized compound PL289 was then treated
with the piperazine head group in DMF with potassium carbonate as base.

Accumulation Experiment
A search of the literature showed that CQ accumulates in the DV of P. falciparum.39;81
82

Previous work in the Peyton Lab has shown that the PL01 behaves like CQ is that it
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accumulates in the DV.75 The experiment used to estimate the uptake of the RCQs by
parasitized red blood cells (PRBCs) is similar to the one used by Kelly, et al..83 Thus,
10 mM solution of PL106 was added to a flask containing 5 mL of PRBCs suspended
in complete medium (10% parasitemia); the initial medium concentration of PL106
was ~ 5 µM. Samples were removed from the flask at various intervals and
centrifuged; the supernatant fluid was then removed and frozen, ready for analysis by
HPLC. PL106 was added to flasks containing both CQS and CQR infected RBCs. The
negative control for this experiment was a flask containing uninfected RBCs, and the
positive control involved infected RBCs interacting with CQ. The experiment was
terminated by adding 10 mM ammonium chloride; this resulted in an increase in the
pH of the DV,83 thus PL106 became unprotonated and released from the DV as shown
in Figure 5.3.
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Figure 5.3: Comparison of CQ and PL106 uptake with P. falciparum strain combination,
showing the drug concentration in the medium after 1 hr with normal RBCs, parasitized RBCs,
and with parasitized RBCs after addition of NH4Cl which liberates the drug from the RBCs.
The grey bars indicate CQ and the dotted bars show PL106. The CQR Dd2 strain clearly has
enhanced uptake of PL106 relative to CQ, while the CQS D6 strain shows the same effect to a
smaller extent.

From this experiment, the amount of drug accumulating in the DV was quantified.
Also, the drug was assessed for possible modifications that may have occurred during
its uptake (modified compounds would have different HPLC retention times). This
experiment was conducted by Jane Xu Kelly (Riscoe Lab, OHSU). From this
experiment it was noted that PL106 accumulated more in CQR and CQS PRBCs than
in normal RBCs. The retention times of the compounds also showed that PL106 was
not modified as a result of its uptake into the RBCs.

Radioisotope Uptake Measurements
The aim of this study was to develop simplified compounds that could overcome CQ
resistance as well as have antimalarial activity. CQ resistance has been linked to
PfCRT, it has been noted that CQR strains of P. falciparum accumulate less CQ in the
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DV; this may be because CQ is transported out of the DV by PfCRT.84 RAs have been
proposed to inhibit PfCRT, and thus reverse CQ resistance.2 The head group for the
simplified RCQs deviates significantly from the pharmacophore proposed by
Bhattarcharjee, et al., hence it may not have optimal RA properties. Despite this
deviation, there is marked improvement in the activity of the synthesized compounds
(See Table 2.3).

An experiment was conducted by Martin, et al., to probe whether the head group of
the simplified RCQs was behaving like a RA.84 In this experiment, the accumulation
of CQ in oocytes encoded with PfCRT both sensitive and resistant types were
conducted. For the positive control, verapamil was used. The difference in uptake of
CQ by the PfCRT CQR oocytes and PfCRT CQS oocytes is small, suggesting that
verapamil is acting as a RA (by inhibiting PfCRT) and preventing CQ from being
transported by PfCRT. For the negative control, it can be observed that the difference
is larger for the uptake of CQ by the PfCRT CQR oocytes than PfCRT CQS oocytes,
reflecting the transport activity of the PfCRT. RCQs PL106, PL154, PL158, and
PL261 (shown in Figure 5.4) have greater inhibition of CQR PfCRT than the negative
control, yet smaller inhibition than verapamil.
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Figure 5.4: Uptake of 3H CQ by PfCRT expressing Xenopus oocytes; pH 6.0. The CQ uptake
is expressed as a percentage of PfCRTCQR. The white bars are for PfCRT CQR oocytes and the
grey bars are for PfCRT CQS oocytes.

This result shows that these compounds do have the ability to behave like RAs, yet to
a smaller extent than PL01 and PL06. This may be due to the fact that there is a
deviation to the pharmacophore proposed by Bhattacharjee et, al., with these
compounds. However, it is evident that PL272 does not behave as a RA since the
difference in CQ uptake for between PfCRT CQR oocytes and PfCRT CQS oocytes is
similar to that of the control (suggesting zero inhibition of CQ transport). Yet the
simplified RCQs can mimic the RA, if they are envisioned as having the two aromatic
head groups, one provided by the quinoline ring and the other provided by the single
aromatic head group, as shown in Figure 5.5. PL272 lacks the two aromatic groups,
and thus does not behave as a RA. This result suggests that the simplified RCQs act as
“mild RAs”, in that they can prevent CQ from being transported by the PfCRT protein
to a smaller extant than classical RAs such as verapamil.
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Protonatable nitrogen

Aromatic head groups

Figure 5.5: PL106 and PL272, PL106 somewhat mimics the RA pharmacophore because it
has two aromatic groups PL272 only has one aromatic head group and thus deviates from the
pharmacophore proposed by Bhattacharjee, et al..

However, PL154 was very potent against P. falciparum CQS D6, with an IC50 value of
0.3 nM against D6, 0.5 nM against P. falciparum CQR Dd2, and 0.1 nM against P.
falciparum CQR 7G8. Further tests were carried out to evaluate for activity against P.
falciparum strains C2B and A6 to probe the possibility of respiratory inhibition in the
parasite. As can be seen in Table 5.1, PL154 was more potent than both quinacrine (a
known respiratory inhibitor)85 and CQ against all four strains tested. C2B is a well
established atovaquone resistant strain.86 A6 is a mutant of D6 derived by Smilkstein,
Risoe, and coworkers, and is resistant to all respiratory inhibitors as far tested.86 So, it
is highly likely that PL154 does not target the mitochondria. Compound PL154 could
still have a very different mode of action than these respiratory inhibitors. If PL154
turned out to be truly a DV drug, then it would be a highly potent DV drug (at least in
vitro).
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Table 5.1: In vitro respiratory inhibition studies (Values in nM).
There is a 30% uncertainty in the IC50 values that may result from
differences in weighing and/or variations in determining IC50 (See
Chapter 7).

P. falciparum
strain

Compound IC50 values in nM
PL154

quinacrine

chloroquine

D6

0.1

4.3

7.3

Dd2

0.6

11.2

112.0

C2B

0.4

13.2

109.7

A6

1.7

8.0

11.8

PL154 seems to inhibit both the ring stage (0.02 nM for CQS D6 strain and 0.05 nM
for CQR Dd2 strain) and the trophozoite stage (0.05 nM for CQS D6 strain, and 0.03
nM for CQR Dd2 strain) of parasite growth by the same order of magnitude. CQ and
clotrimazole have been reported in literature, to be more specific to the ring stage by 1
order of magnitude compared to the trophozoite stage.21;87;88 During the ring stage and
the trophozoite stage, there is the highest metabolic activity. At the ring stage the first
signs of the malaria pigment are observed. Since PL154 is a CQ-like compound it is
expected to have potency by at least partly the same mechanism of action as CQ. CQ
is proposed to either cap the ends of growing heme chains or to bind via pi pi bonds to
heme dimers. This action is proposed to be most highest during the ring stage and the
trophozoite stage.89
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Heme Binding and β-Hematin Inhibition
CQ is presumed to exert its antimalarial action through binding with heme which is
toxic to the parasite.7 Heme is a by product of hemoglobin digestion in the parasite
and is sequestered into hemozoin by the parasite; hemozoin is not toxic to the
parasite.6 The simplified RCQs were thus evaluated for heme binding by Shawheen
Shomloo (Peyton Lab, Portland, Oregon),90 to check whether they behave like CQ.
For heme-drug binding studies, CQ or PL compound was dissolved in distilled water,
methanol, or dimethyl sulfoxide (DMSO), depending on solubility of the respective
compounds; they were also sonicated to ensure complete solubility. A stock solution
of heme was prepared by dissolving heme chloride in NaOH. At the beginning of each
experiment, the stock heme solution was diluted in phosphate buffer and allowed to
equilibrate for four hours. Optical titrations with each compound were performed by
successive addition of aliquots of its stock solution to the heme solution. The pH was
monitored throughout the procedure with only negligible changes. Equilibrium
binding constants were determined by nonlinear least-squares analysis.91 The results
for the heme binding studies are shown in Figure 5.6.
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Figure 5.6: Heme binding and β-hematin inhibition studies for the simplified RCQs. The scale
for the line graph is on the right and the scale for the bar graph is on the left.

The results show that the PL compounds generally have a LogKa of about 5 which is
an indication that there is strong binding with heme. These results also show that these
compounds bind to heme within 72 hrs, a similar affinity as does CQ.

β-Hematin, which is synthetic, has an identical crystal structure to hemozoin found in
malaria parasites.92 CQ and CQ-like compounds can prevent the formation of βhematin in vitro.90 An experiment was thus conducted by Shawheen Shomloo, to
evaluate the inhibition constants for β-hematin formation by the simplified RCQ
molecules. In this experiment the optimal heme and Tween20 concentrations for
promoting heme crystallization were calculated by the procedure described by Huy,
2002.93 The RCQ compounds were screened for their inhibitory capacity, and IC50
values were determined. A series of solutions was made, consisting of varying
concentrations of the compound under study in distilled, acetate buffer, heme solution
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freshly buffered by sodium acetate, and Tween20 solution. The mixtures were
incubated for 24 hours at 37°C,94 then mixed and transferred to a cuvette for
absorbance reading. IC50 values were calculated by (Dmax – Dinitial ) / 2 where Dmax
represents the lowest concentration of compound under study to provide maximal
absorbance readings indicating maximal free heme, and Dinitial represents the lowest
concentration of drug to provide any increase in absorbance over a solution with no
drug. The results for the heme inhibition studies are shown in Figure 5.6. From these
results we see that most of the compounds are more potent than CQ in inhibiting βhematin formation. However PL228 and PL229 (Table 3.1) are less potent than CQ in
inhibiting β-hematin formation. This is an anomaly because these compounds have the
quinoline ring which is required for inhibition of β-hematin formation. One
explanation is that the RA-moiety aromatic head group influences β-hematin
formation; this group is absent in PL228 and PL229. This result does not, however,
correlate well with the antimalarial IC50 values of these compounds, and this may be
because these compounds prevent malaria via a different mechanism compared to the
single aromatic head group compounds. PL192 has two quinoline rings, which
cumulatively result in increased inhibition of β-hematin formation. It is also
interesting to note that there is no correlation between heme binding and β-hematin
inhibition for the simplified RCQs.
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CHAPTER 6
Summary and Conclusions

Malaria is a major health problem, due to the increase in the malaria parasite’s
resistance to current drugs, there is a need to discover compounds with novel scaffolds
that may not have been exposed to the parasites, and so would not exhibit resistance.
In addition, there is a need keep remedies for malaria inexpensive, since this disease
mainly affects developing countries. CQ was an effective antimalarial drug but lost its
effectiveness due to the development of CQR strains of malaria. RAs have been
shown to reverse CQ resistance and so the focus of this research has been to develop
compounds composed of a RA head group attached to a CQ like portion. In this
research, the RA head group has been simplified from the branched aromatic groups
described by Bhattacharjee, et al., to a single aromatic group. This approach has been
shown to be quite viable as a potential drug candidate PL106 was synthesized. This
compound was orally available in mice and was shown to have no visible toxicity to
human cells as well as mice. Further studies may need to be carried out on PL106
before human trials can be done on it.

From the studies reported in this document, it was noted that the simplified RCQ
could accommodate several changes without major losses in activity. It was noted that
the linker length between the protonatable nitrogen and the head group could be
varied. Also it was noted that the linker length between the quinoline ring and the
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protonatable nitrogen could be varied as well. These results were in agreement with
previous studies carried out in the Peyton Lab.78 It was also noted that the head group
could tolerate a change from aromatic to aliphatic. Mechanistic studies on the head
group showed that the head group on its own does not have RA activity, however
when linked to the quinoline ring RA activity was observed. This finding may be due
to the fact that the quinoline ring and the single aromatic head group satisfy the
condition of two branched aromatic groups proposed by Bhattacharjee, et al.. The
single aromatic head group on its own does not satisfy the pharmacophore proposed
by Bhattacharjee, et al..

Further work on this project which is beyond the scope of this dissertation will involve
more in vivo tests to determine the safety of these compounds.
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CHAPTER 7
Materials and Methods

This section gives an outline of the synthesis that was used to make the different
antimalarial compounds as well as their intermediates. Names of compounds were
generated using ChemBioDraw 11.0.1. The purity of the compounds was detected by a
Varian Polaris Binary HPLC system, measuring by UV detection at 254 nm and 325
nm, using a Varian ProStar 325 UV/Vis dual wavelength detector. HPLC method A
was done with a Microsorb-MV 100-5 C18 250 mm X 4.6 mm column, eluting with
95 % methanol and 5 % water for 30 minutes. HPLC method B was done with an
AscentisTM 5µm C18 150 mm X 4.6 mm column, eluting with 95 % water and 5 %
acetonitrile for 30 minutes. All reagents and solvents were purchased from Aldrich
and used as supplied. 1H NMR and 13C NMR and 2D NMR spectra were detected on a
Bruker 400 MHz spectrometer. Splitting patterns were described as singlet (s), doublet
(d), triplet (t), quartet (q), pintet (p), doublet of doublets (dd), doublet of triplets (dt),
doublet of doublet of doublets (ddd), multiplet (m), and broad (br). Mass spectrometry
was performed on a Bruker microOTOF-Q instrument. The method use was
electrospray ionization (ESI) in the positive mode, at a flow rate of 0.4 mL/min with
1:1 methanol water. Each of the compounds made had a CQ like portion linked RA
like portion. Outlined is the method for the synthesis of PL91, the same method was
used to make other compounds with varying piperazine head groups.
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Synthesis of PL16 3-(7-chloroquinolin-4-ylamino)propan-1-ol
25.48 g (129 mmol) of 4,7-dichloroquinoline was added to 122 mL (157 mmol) of 3amino-1-propanol and heated at ~135oC for 48 hrs. The reaction was verified by Thin
layer Chromatography (TLC) in 100% ethyl acetate (EA). The solution was allowed to
cool to room temperature and then poured into 500 mL water with stirring. The
precipitate that formed was chilled in an ice bath. The solid was filtered off and
washed with water. The solid was allowed to air dry in the fume hood and then
recrystallized twice in EA. 22.50 g (95 mmol, 74% yield) of PL 16 was obtained.

Synthesis of PL28 2-(7-chloroquinolin-4-ylamino)ethanol

A mixture of 4,7-dichloroquinoline 4.95 g (25 mmol) and ethanolamine 15.27 g (250
mmol) was heated with stirring at ~135oC for 24 hrs. After cooling, the reaction was
poured into 150 mL water and filtered. After air drying the solid was boiled in 100 mL
methanol, allowed to cool to room temperature then cooled in ice. The solid was
filtered, and then washed with a small amount of ice cold methanol to give PL28 3 g
(13 mmol, 54% yield) as an off-white solid.

Synthesis of PL29 3-(7-chloroquinolin-4-ylamino)propyl methanesulfonate
0.5 g (2.1 mmol) of PL16 was treated as a suspension in dry 15 ml dichloromethane
with 0.43 g (4.2 mmol) of triethylamine as base. The mixture was chilled over an
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ice/salt (<0oC) bath then 0.25g (2.2 mmol) of methane sulfonyl chloride was added to
the mixture for ~3 minutes with stirring. The reaction was allowed to proceed for 30
minutes, and then extracted with 30 ml aqueous sodium bicarbonate, then three times
with 10 ml dichloromethane. The mixture was dried over magnesium sulfate. Finally,
the dichloromethane was evaporated off. The product was weighed and used as
starting material for a lot of the compounds made in this article.

Synthesis of PL30 2-(7-chloroquinolin-4-ylamino)ethyl methanesulfonate

To a suspension of PL28 1.5 g (6.7 mmol) in anhydrous 25 mL dichloromethane under
a nitrogen atmosphere was added 2 mL (14.3 mmol) triethylamine. The mixture was
cooled to bellow 0oC. 0.57 mL (7.4 mmol) of methanesulfonylchloride was added
slowly, keeping the temperature below 5oC, and the reaction was stirred in an ice bath
for 1 hr. The reaction was added to a 100 mL solution of saturated sodium
bicarbonate. The aqueous layer was extracted with 2 X 20 mL dichloromethane. The
combined organic extracts were evaporated to leave an off-white product PL30 1.19 g
(4 mmol, 59%).
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Synthesis of PL91 7-chloro-N-(3-(4-phenylpiperazin-1-yl)propyl)quinolin-4amine

0.3 g (1.0 mmol) of the PL29 was added to the 0.32 g (1.2 mmol) of the 1phenylpiperazine in 15 ml dry tetrahydrofuran and 0.27 g (2 mmol) of triethyl amine
as base. This mixture was refluxed for one day. The mixture was then extracted with
30 ml of sodium bicarbonate, then three 10 ml volumes ethyl acetate. The organic
layer was rinsed with 10 mL brine. Then resultant mixture was dried over magnesium
sulfate. Finally, the ethyl acetate was removed by rotoevaporation. The solid product
was precipitated from an ethanol solvent. The cream compound was filtered, weighed
0.16 g (0.4 mmol, 44% yield) and characterized by 1H-NMR, HPLC & MS. HPLC
(method B) tR = 8.28 (99% Pure).

1

H-NMR (CDCl3) δ 1.88(2H, q, J=5.4 Hz),

2.59(2H, t, J=5.5 Hz), 2.64(4H, t, J=4.7 Hz), 3.23(4H, t, J=4.7 Hz), 3.31(2H, dt, J=5.6
Hz), 6.85(1H, t, J=7.3 Hz), 6.9(2H, d, J=8.1 Hz), 7.10(1H, dd, J=2.0, 8.9 Hz),
7.25(2H, t, J=8.4 Hz), 7.32(1H, s), 7.71(1H, d, 9.0 Hz), 7.84(1H, d, J=2.0 Hz),
8.42(1H, d, J=5.4 Hz); ESIMS [M + H]+ calcd for C22H25ClN4 381.1841, found
381.1831.
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Synthesis of PL106 7-chloro-N-(3-(4-(pyridin-2-yl)piperazin-1yl)propyl)quinolin-4-amine

0.49 g (1.56 mmol) of PL29 was added to 0.3 g (1.86 mmol) of 1-(2Pyridyl)piperazine and 0.43 g (3.11 mmol) triethylamine in 30 mL of chloroform. The
mixture was refluxed for one day and then extracted with 30 mL sodium bicarbonate
and 3 X 10 mL of chloroform. The chloroform was evaporated off and the crude
product was columned twice on silica with a 50:50 methanol:ethylacetate solvent
mixture. 0.26 g (0.68 mmol, 44 % yield) of tan crystals was obtained as product.

HPLC (method B) tR = 5.68 (99% Pure). ¹H NMR δ (ppm)(CH3OH-d4): 8.39 (1 H, d,
J = 5.64 Hz), 8.11-8.10 (2 H, m), 7.80 (1 H, d, J = 2.18 Hz), 7.59 (1 H, ddd, J = 8.64,
7.13, 2.00 Hz), 7.40 (1 H, dd, J = 9.01, 2.20 Hz), 6.85 (1 H, d, J = 8.64 Hz), 6.71 (1 H,
dd, J = 7.11, 5.03 Hz), 6.59 (1 H, d, J = 5.69 Hz), 3.57 (4 H, t, J = 4.99 Hz), 3.49 (2 H,
t, J = 6.80 Hz), 2.64-2.62 (6 H, m), 2.02 (2 H, t, J = 7.01 Hz). ¹³C NMR δ
(ppm)(CH3OH-d4): 152.5, 149.7, 148.5, 139.3, 136.4, 127.7, 126.0, 124.3, 118.8,
114.8, 109.2, 99.7, 57.5, 54.2, 46.5, 42.6, 26.1. ESIMS [M + H]+ calcd for C21H24ClN5
382.1793, found 382.1784.

Synthesis of PL109 7-chloro-N-(3-(4-(pyridin-4-yl)piperazin-1yl)propyl)quinolin-4-amine
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0.44 g (1.4 mmol) of PL29 was added to 0.25 g (1.5 mmol) of 1-(2-Pyridyl)piperazine
and 0.28 g (2.8 mmol) in 30 mL of acetonitrile. The mixture was refluxed for 1 day
and then extracted with 30 mL sodium bicarbonate and 3 X 10 mL of chloroform. The
chloroform was evaporated off and the crude product was columned twice on silica
with a 50:50 methanol:ethylacetate solvent mixture. 0.23 g (0.6 mmol, 43 % yield) of
tan crystals was obtained as product.¹H NMR δ (ppm)(CH3OH-d4): 8.26 (1 H, d, J =
5.63 Hz), 8.05-7.99 (2 H, m), 7.98 (1 H, d, J = 9.03 Hz), 7.68 (1 H, d, J = 2.19 Hz),
7.28 (1 H, dd, J = 9.00, 2.19 Hz), 6.74 (2 H, d, J = 6.08 Hz), 6.52-6.45 (1 H, m), 3.403.31 (6 H, m), 2.56-2.46 (6 H, m), 1.89 (2 H, p, J = 6.99 Hz). ESIMS [M + H]+ calcd
for C21H24ClN5 382.1786, found 382.1793

Synthesis of PL110 N-(3-(4-(biphenyl-4-yl)piperazin-1-yl)propyl)-7chloroquinolin-4-amine

0.5 g (1.59 mmol) of PL29 was added to 0.45 g (1.91 mmol) of 1-(biphenyl-4yl)piperazine and 0.32 g (3.17 mmol) of triethylamine in 15 mL of tetrahydrofuran.
The mixture was allowed to reflux for one day and then extracted with 30 mL sodium
bicarbonate and 3 X 10 mL chloroform. The chloroform was evaporated off and the
crude product columned on silica with a 25:75 methanol: ethyl acetate solvent
mixture. The product was in the form of white crystals and a yield of 0.16 g (0.35
mmol, 21.9 % yield). ¹H NMR δ (ppm)(CHCl3-d): 8.48 (1 H, d, J = 5.77 Hz), 8.09 (1
H, s), 7.91 (1 H, d, J = 8.97 Hz), 7.62-7.57 (4 H, m), 7.44 (2 H, t, J = 7.58 Hz), 7.3667

7.31 (1 H, m), 7.09-7.02 (2 H, m), 6.41 (1 H, d, J = 5.82 Hz), 3.54-3.48 (2 H, m), 3.42
(4 H, t, J = 4.74 Hz), 2.82 (4 H, t, J = 4.69 Hz), 2.80-2.74 (2 H, m), 2.10-2.03 (2 H,
m).

Synthesis of PL111 N-(3-(4-(biphenyl-3-yl)piperazin-1-yl)propyl)-7chloroquinolin-4-amine

0.6 g (1.9 mmol) of PL29 was added to 0.55 g (2.29 mmol) of 1-(biphenyl-3yl)piperazine and 0.39 g (3.81 mmol) of triethylamine in 15 mL of tetrahydrofuran.
The mixture was allowed to reflux for one day and then extracted with 30 mL sodium
bicarbonate and 3 X 10 mL chloroform. The chloroform was evaporated off and the
crude product columned on silica with a 25:75 methanol: ethyl acetate solvent
mixture. The product was in the form of a white powder and a yield of 0.16 g (0.35
mmol, 18.4 % yield). HPLC (method b) tR = 11.51 (98% Pure). ¹H NMR δ
(ppm)(CHCl3-d): 8.52 (1 H, d, J = 5.35 Hz), 7.93 (1 H, d, J = 2.15 Hz), 7.82 (1 H, d, J
= 8.94 Hz), 7.63-7.58 (2 H, m), 7.47-7.32 (5 H, m), 7.24 (1 H, dd, J = 8.00, 2.28 Hz),
7.20-7.13 (2 H, m), 6.98 (1 H, dd, J = 8.30, 2.49 Hz), 6.36 (1 H, d, J = 5.41 Hz), 3.43
(2 H, d, J = 5.08 Hz), 3.42-3.37 (5 H, m), 2.77 (4 H, t, J = 4.75 Hz), 2.74-2.68 (2 H,
m), 2.05-1.97 (2 H, m).¹³C NMR δ (ppm)(CHCl3-d): 160.9, 152.4, 151.6, 147.9,
145.3, 141.4, 134.6, 129.8, 129.2, 127.5, 125.3, 121.9, 122.3, 119.6, 115.4, 113.7,
112.5, 98.4, 96.4, 58.8, 53.7, 49.5, 44.1, 24. ESIMS [M + H]+ calcd for C28H29ClN4
457.2154, found 457.2171.
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Synthesis of PL112 N-(3-(4-(biphenyl-2-yl)piperazin-1-yl)propyl)-7chloroquinolin-4-amine

0.6 g (1.9 mmol) of PL29 was added to 0.55 g (2.29 mmol) of 1-(biphenyl-2yl)piperazine and 0.39 g (3.81 mmol) of triethylamine in 15 mL of tetrahydrofuran.
The mixture was allowed to reflux for one day and then extracted with 30 mL sodium
bicarbonate and 3 X 10 mL chloroform. The chloroform was evaporated off and the
crude product was recrystallized with 25:75 methanol: ethyl acetate solvent mixture.
The product was in the form of a brown powder and a yield of 0.12 g (0.26 mmol,
13.8 % yield). HPLC (method B) tR = 11.38 (95% Pure). ¹H NMR δ (ppm)(CHCl3-d):
8.49 (1 H, d, J = 5.44 Hz), 7.96 (1 H, d, J = 2.13 Hz), 7.88 (1 H, d, J = 8.94 Hz), 7.687.63 (2 H, m), 7.60 (1 H, s), 7.45-7.35 (3 H, m), 7.35-7.26 (3 H, m), 7.20-7.11 (2 H,
m), 6.32 (1 H, d, J = 5.48 Hz), 3.38 (2 H, q, J = 5.17 Hz), 3.01 (4 H, t, J = 4.72 Hz),
2.65-2.59 (2 H, m), 2.50 (4 H, s), 1.93 (2 H, p, J = 5.46 Hz).¹³C NMR δ (ppm)(CHCl3d): 151.7, 150.7, 149.9, 141.0, 135.2, 134.9, 131.7, 128.9, 128.6, 128.4, 128.2, 126.8,
124.9, 123.1, 122.3, 118.0, 117.4, 98.4, 58.7, 53.7, 51.1, 44.4, 23.4. ESIMS [M + H]+
calcd for C28H29ClN4 457.2145, found 457.215

Synthesis of PL154 7-chloro-N-(3-(4-(4-chlorophenyl)piperazin-1yl)propyl)quinolin-4-amine
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0.63 g (2 mmol) of PL29 was added to 0.47 g (2.4 mmol) of 1-(4chlorophenyl)piperazine and 0.39 g (4 mmol) of triethylamine in 15 mL of
tetrahydrofuran. The mixture was allowed to reflux for one day and then extracted
with 30 mL sodium bicarbonate and 3 X 10 mL chloroform. The chloroform was
evaporated off and the crude product was recrystallized with 25:75 methanol: ethyl
acetate solvent mixture. The product was in the form of an off white powder and a
yield of 0.02 g (0.05 mmol, 2.4 % yield). HPLC (method A) tR = 5.91 (98% Pure). ¹H
NMR δ (ppm)(CHCl3-d): 8.52 (1 H, d, J = 5.36 Hz), 7.93 (1 H, d, J = 2.15 Hz), 7.78 (1
H, d, J = 8.94 Hz), 7.29-7.27 (2 H, m), 7.24 (1 H, s), 7.20 (1 H, dd, J = 8.91, 2.16 Hz),
6.92-6.87 (2 H, m), 6.36 (1 H, d, J = 5.40 Hz), 3.42 (2 H, q, J = 5.32 Hz), 3.32-3.26 (4
H, m), 2.74 (4 H, t, J = 4.82 Hz), 2.73-2.67 (2 H, m), 2.00 (2 H, p, J = 5.58 Hz).
ESIMS [M + H]+ calcd for C22H24Cl2N4 415.1451, found 415.1460.

Synthesis of PL155 7-chloro-N-(3-(4-(3,4-dichlorophenyl)piperazin-1yl)propyl)quinolin-4-amine

0.53 g (1.68 mmol) of PL29 was added to 0.47 g (2.0 mmol) of 1-(3,4dichlorophenyl)piperazine and 0.34 g (3.4 mmol) of triethylamine in 15 mL of
tetrahydrofuran. The mixture was allowed to reflux for one day and then extracted
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with 30 mL sodium bicarbonate and 3 X 10 mL chloroform. The chloroform was
evaporated off and the crude product was recrystallized in methanol. The product was
in the form of gold crystals and weighed 0.15 g (0.3 mmol, 19.8 %). ¹H NMR δ
(ppm)( CHCl3-d): 8.52 (1 H, d, J = 5.36 Hz), 7.93 (1 H, d, J = 2.15 Hz), 7.74 (1 H, d, J
= 8.94 Hz), 7.33 (1 H, d, J = 8.89 Hz), 7.26 (1 H, s), 7.21 (1 H, dd, J = 8.90, 2.17 Hz),
7.07 (1 H, s), 7.01 (1 H, d, J = 2.87 Hz), 6.78 (1 H, dd, J = 8.91, 2.88 Hz), 6.36 (1 H,
d, J = 5.40 Hz), 3.44-3.37 (2 H, m), 3.29 (4 H, t, J = 4.84 Hz), 2.73-2.64 (6 H, m),
2.05-1.95 (2 H, m). ESIMS [M + H]+ calcd for C22H23Cl3N4 449.1068, found
449.1061.

Synthesis of PL156 7-chloro-N-(3-(4-(4-fluorophenyl)piperazin-1yl)propyl)quinolin-4-amine

0.58 g (1.84 mmol) of PL29 was added to 0.40 g (2.2 mmol) of 1-(4fluorophenyl)piperazine and 0.37 g (3.7 mmol) of triethylamine in 15 mL of
tetrahydrofuran. The mixture was allowed to reflux for one day and then extracted
with 30 mL saturated sodium bicarbonate solution and 3 X 10 mL chloroform. The
chloroform was evaporated off and the crude product was recrystallized in a 25:75
methanol:ethylacetate solution. The product was in the form of a white powder and
weighed 0.26 g (0.7 mmol, 35.4 %). HPLC (method A) tR = 5.91 (99% Pure). ¹H
NMR δ (ppm)( CHCl3-d): 8.52 (1 H, d, J = 5.36 Hz), 7.93 (1 H, d, J = 2.16 Hz), 7.80
(1 H, d, J = 8.94 Hz), 7.31 (1 H, s), 7.20 (1 H, dd, J = 8.91, 2.17 Hz), 7.06-6.98 (2 H,
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m), 6.97-6.91 (2 H, m), 6.35 (1 H, d, J = 5.40 Hz), 3.41 (2 H, q, J = 5.29 Hz), 3.273.22 (4 H, m), 2.77-2.72 (4 H, m), 2.73-2.67 (2 H, m), 2.06-1.96 (2 H, m). ESIMS [M
+ H]+ calcd for C22H24ClFN4 399.1746, found 399.1753.

Synthesis of PL157 7-chloro-N-(3-(4-(4-methoxyphenyl)piperazin-1yl)propyl)quinolin-4-amine

0.69 g (2.2 mmol) of PL29 was added to 0.51 g (2.6 mmol) of 1-(4methoxyphenyl)piperazine and 0.44 g (4.4 mmol) of triethylamine in 15 mL of
tetrahydrofuran. The mixture was allowed to reflux for one day and then extracted
with 30 mL saturated sodium bicarbonate solution and 3 X 10 mL chloroform. The
chloroform was evaporated off and the crude product was recrystallized in a 25:75
methanol:ethylacetate solution. The product was in the form of gold crystals and
weighed 0.09 g (0.2 mmol, 10 %). HPLC (method A) tR = 6.88 (98% Pure). ¹H NMR
δ (ppm)( CHCl3-d): 8.51 (1 H, d, J = 5.36 Hz), 7.92 (1 H, d, J = 2.16 Hz), 7.83 (1 H, d,
J = 8.94 Hz), 7.43 (1 H, s), 7.21 (1 H, dd, J = 8.91, 2.17 Hz), 6.98-6.93 (2 H, m), 6.936.87 (2 H, m), 6.33 (1 H, d, J = 5.40 Hz), 3.86-3.71 (3 H, m), 3.40 (2 H, q, J = 5.23
Hz), 3.22 (4 H, t, J = 4.73 Hz), 2.78-2.72 (4 H, m), 2.71-2.66 (2 H, m), 2.03-1.95 (2H,
m). ESIMS [M + H]+ calcd for C23H27ClN4O 411.1946, found 411.1949.
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Synthesis of PL158 7-chloro-N-(3-(4-(4-(trifluoromethyl)phenyl)piperazin-1yl)propyl)quinolin-4-amine
0.69 g (2.2 mmol) of PL29 was added to 0.61 g (2.6 mmol) of 1-(4methoxyphenyl)piperazine and 0.44 g (4.4 mmol) of triethylamine in 15 mL of
tetrahydrofuran. The mixture was allowed to reflux for one day and then extracted
with 30 mL saturated sodium bicarbonate solution and 3 X 10 mL chloroform. The
chloroform was evaporated off and the crude product was recrystallized in a 25:75
methanol:ethylacetate solution. The product was in the form of white crystals and
weighed 0.03 g (0.07 mmol, 3.1 %). HPLC (method A) tR = 5.88 (99% Pure). ¹H
NMR δ (ppm)( CHCl3-d): 8.52 (1 H, d, J = 5.35 Hz), 7.93 (1 H, d, J = 2.16 Hz), 7.75
(1 H, d, J = 8.94 Hz), 7.54 (2 H, d, J = 8.60 Hz), 7.20 (1 H, dd, J = 8.90, 2.17 Hz), 7.11
(1 H, s), 6.98 (2 H, d, J = 8.59 Hz), 6.36 (1 H, d, J = 5.39 Hz), 3.46-3.38 (6 H, m), 2.74
(4 H, t, J = 4.91 Hz), 2.72-2.66 (2 H, m), 2.01 (2 H, p, J = 5.65 Hz). ESIMS [M + H]+
calcd for C23H24ClF3N4 449.1714, found 449.1729.

Synthesis of PL159 4-(4-(3-(7-chloroquinolin-4-ylamino)propyl)piperazin-1yl)phenol
0.51 g (1.6 mmol) of PL29 was added to 0.31 g (1.7 mmol) of 1-(4hydroxyphenyl)piperazine and 0.23 g (1.62 mmol) of potassium carbonate in 20 mL of
acetonitrile. The mixture was allowed to reflux for 24 hrs and then the acetonitrile was
evaporated off. The remaining residue was dissolved in 20 mL of chloroform and then
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extracted with 30 mL saturated sodium bicarbonate solution and 3 X 10 mL
chloroform. The chloroform was evaporated off and the crude product was
recrystallized in a 25:75 methanol:ethylacetate solution. The product was in the form
of a grey powder and weighed 0.05 g (0.1 mmol, 8 %). ¹H NMR δ (ppm)(CH3OH-d4):
8.38 (1 H, d, J = 5.64 Hz), 8.11 (1 H, d, J = 9.01 Hz), 7.80 (1 H, d, J = 2.17 Hz), 7.39
(1 H, dd, J = 9.01, 2.19 Hz), 6.94-6.88 (2 H, m), 6.77-6.72 (2 H, m), 6.58 (1 H, d, J =
5.68 Hz), 3.52-3.45 (2 H, m), 3.16-3.08 (4 H, m), 2.72-2.65 (4 H, m), 2.62 (2 H, t, J =
7.16 Hz), 2.05-1.96 (2 H, m). ESIMS [M + H]+ calcd for C22H26ClON4 397.1790,
found 397.1783.

Synthesis of PL163 7-chloro-N-(3-(4-p-tolylpiperazin-1-yl)propyl)quinolin-4amine

0.70 g (2.2 mmol) of PL29 was added to 0.47 g (2.7 mmol) of 1-(4methoxyphenyl)piperazine and 0.45 g (4.4 mmol) of triethylamine in 15 mL of
tetrahydrofuran. The mixture was allowed to reflux for one day and then extracted
with 30 mL saturated sodium bicarbonate solution and 3 X 10 mL chloroform. The
chloroform was evaporated off and the crude product was recrystallized in a 25:75
methanol:ethylacetate solution. The product was in the form off gold crystals and
weighed 0.110 g (0.3 mmol, 12.5 % yield). HPLC (method B) tR = 9.11 (96% Pure).
¹H NMR δ (ppm)( CHCl3-d): 8.51 (1 H, d, J = 5.36 Hz), 7.92 (1 H, d, J = 2.16 Hz),
7.82 (1 H, d, J = 8.94 Hz), 7.41 (1 H, s), 7.21 (1 H, dd, J = 8.91, 2.18 Hz), 7.14 (2 H,
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d, J = 8.21 Hz), 6.91 (2 H, d, J = 8.35 Hz), 6.34 (1 H, d, J = 5.40 Hz), 3.41 (2 H, q, J =
5.25 Hz), 3.29 (4 H, t, J = 4.77 Hz), 2.75 (4 H, t, J = 4.75 Hz), 2.73-2.67 (2 H, m),
2.32 (3 H, s), 2.06-1.96 (2 H, m). ¹³C NMR δ (ppm)(CHCl3-d): 152.2, 150.5, 149.2,
149.0, 134.7, 129.8, 128.7, 124.8, 122.1, 117.4, 116.6, 98.5, 58.7, 53.7, 50.0, 44.4,
23.6, 20.5. ESIMS [M + H]+ calcd for C23H27ClN4 395.1997, found 395.1984.

Synthesis of PL192 N,N'-(3,3'-(piperazine-1,4-diyl)bis(propane-3,1-diyl))bis(7chloroquinolin-4-amine)

1.64 g (8.3 mmol) of 4,7-dichloroquinoline was added to 0.79 g of (3.9 mmol)3,3'(piperazine-1,4-diyl)dipropan-1-amine and 6 g (63.8 mmol) of then heated at ~125oC
for 4 hrs( temperature and time control were critical as dark tarry by products formed
with large variations in time and temperature). The solution was allowed to cool to
room temperature and then diluted with 40 mL dichloromethane. The solution was
then washed with 6 X 20 mL 2 M sodium hydroxide and then 30 mL brine. The
resulting solution was dried over magnesium sulphate. After the solvent was
evaporated the solid product was recrystallized in 25:75 methanol:ethylacetate
solution. 0.020 g (0.04 mmol, 1% yield) of an off white crystal powder was obtained.
HPLC (method B) tR = 6.38 (96% Pure). ¹H NMR δ (ppm)( CHCl3-d): 8.53 (2 H, d, J
= 5.35 Hz), 7.95 (2 H, dd, J = 6.47, 2.15 Hz), 7.91-7.83 (2 H, m), 7.37 (2 H, s), 7.377.28 (2 H, m), 6.40-6.32 (2 H, m), 3.47-3.36 (4 H, m), 2.78-2.72 (8 H, m), 2.06-1.96
(4 H, m), 1.71 (4 H, s).¹³C NMR δ (ppm)( CHCl3-d): 152.3, 150.5, 149.2, 134.6,
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128.8, 124.7, 122.2, 117.5, 98.7, 59.0, 53.7, 44.3, 23.6. ESIMS [M + H]+ calcd for
C28H32Cl2N6 523.2138, found 523.2147.

Synthesis of PL223 7-chloro-N-(3-(4-(naphthalen-1-ylmethyl)piperazin-1yl)propyl)quinolin-4-amine

0.70 g (2.2 mmol) of PL29 was added to 0.6 g (2.7 mmol) of 1-(naphthalen-1ylmethyl)piperazine and 0.45 g (4.4 mmol) of triethylamine in 15 mL of
tetrahydrofuran. The mixture was allowed to reflux for one day and then extracted
with 30 mL saturated sodium bicarbonate solution. The aqueous layer was further
extracted with 3 X 10 mL chloroform. The chloroform was evaporated off and the
crude product was recrystallized in a 25:75 methanol:ethylacetate solution. The
product was in the form of pale yellow crystals and weighed 0.120 g (0.3 mmol, 12.1
% yield). HPLC (method B) tR = 9.69 (98% Pure). ¹H NMR δ (ppm)(CHCl3-d): 1.93
(2 H, p, J = 5.40 Hz), 2.54-2.74 (10 H, m), 3.37 (2 H, q, J = 5.14 Hz), 4.03 (2 H, s),
6.32 (1 H, d, J = 5.39 Hz), 7.35 (1 H, dd, J = 8.91, 2.18 Hz), 7.42-7.60 (4 H, m), 7.64
(1 H, s), 7.79-7.91 (2 H, m), 7.90-7.98 (2 H, m), 8.33 (1 H, d, J = 8.22 Hz), 8.51 (1 H,
d, J = 5.34 Hz).¹³C NMR δ (ppm)(CHCl3-d): 23.4, 44.6, 53.3, 53.7, 58.8, 61.4, 98.5,
117.5, 122.6, 124.6, 124.7, 125.2, 125.7, 125.8, 127.6, 128.2, 128.5, 128.7, 132.6,
133.6, 133.9, 134.6, 149.2, 150.6, 152.3. ESIMS [M + H]+ calcd for C27H29ClN4
445.2154, found 445.2154.
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Synthesis of PL227 7-chloro-N-(3-(4-phenethylpiperazin-1-yl)propyl)quinolin-4amine

0.60 g (1.9 mmol) of PL29 was added to 0.44 g (2.3 mmol) of 1-phenethylpiperazine
and 0.38 g (3.8 mmol) of triethylamine in 15 mL of tetrahydrofuran. The mixture was
allowed to reflux for one day and then extracted with 30 mL saturated sodium
bicarbonate solution. The aqueous layer was further extracted with 3 X 10 mL
chloroform. The chloroform was evaporated off and the crude product was
recrystallized in ethyl acetate solution. The product was in the form of pale tan crystals
and weighed 0.29 g (0.7 mmol, 37.2 % yield). HPLC (method B) tR = 7.6 (99% Pure).
¹H NMR δ (ppm)(CHCl3-d): 1.91-2.00 (2 H, m), 2.52-2.86 (12 H, m), 2.83-2.90 (2 H,
m), 3.39 (2 H, q, J = 5.17 Hz), 6.33 (1 H, d, J = 5.41 Hz), 7.20-7.25 (3 H, m), 7.297.35 (3 H, m), 7.56 (1 H, s), 7.89 (1 H, d, J = 8.94 Hz), 7.94 (1 H, d, J = 2.15 Hz), 8.51
(1 H, d, J = 5.36 Hz).¹³C NMR δ (ppm)(CHCl3-d): 152.2, 150.6, 149.2, 140.1, 134.7,
128.7, 128.7, 128.5, 126.2, 124.7, 122.4, 117.5, 98.5, 60.7, 58.8, 53.6, 53.4, 44.5, 33.7,
23.4. ESIMS [M + H] + calcd for C23H29ClN4 409.2154, found 409.2156.

Synthesis of PL228 7-chloro-N-(3-(4-(cyclohexylmethyl)piperazin-1yl)propyl)quinolin-4-amine

0.40 g (1.3 mmol) of PL29 was added to 0.28 g (1.5 mmol) of 1(cyclohexylmethyl)piperazine and 0.26 g (2.6 mmol) of triethylamine in 15 mL of
tetrahydrofuran. The mixture was allowed to reflux for one day and then extracted
with 30 mL saturated sodium bicarbonate solution. The aqueous layer was further
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extracted with 3 X 10 mL chloroform. The chloroform was evaporated off and the
crude product was recrystallized in ethyl acetate solution. The product was in the form
of pale orange crystals and weighed 0.050 g (0.1 mmol, 9.8 % yield). HPLC (method
B) tR = 7.68 (96% Pure). ¹H NMR δ (ppm)(CHCl3-d): 0.83-0.98 (2 H, m), 1.14-1.32
(3 H, m), 1.73 (7 H, d, J = 14.81 Hz), 1.82 (2 H, d, J = 13.12 Hz), 1.90-1.99 (2 H, m),
2.23 (2 H, d, J = 7.18 Hz), 2.51-2.70 (8H, m), 3.38 (2 H, q, J = 5.12 Hz), 6.31 (1 H, d,
J = 5.43 Hz), 7.33 (1 H, dd, J = 8.90, 2.19 Hz), 7.75 (1 H, s), 7.90-7.96 (2 H, m), 8.50
(1 H, d, J = 5.38 Hz). ¹³C NMR δ (ppm)(CHCl3-d): 23.2, 26.2, 27.0, 31.9, 35.3, 44.6,
53.7, 53.8, 58.6, 66.0, 98.4, 117.7, 122.6, 124.2, 128.6, 134.9, 149.0, 150.5, 152.2.
ESIMS [M + H]+ calcd for C23H33ClN4 401.2467, found 401.2468.

Synthesis of PL229 7-chloro-N-(3-(4-cyclohexylpiperazin-1-yl)propyl)quinolin-4amine

0.45 g (1.4 mmol) of PL29 was added to 0.28 g (1.7 mmol) of 1-cyclohexylpiperazine
and 0.29 g (2.9 mmol) of triethylamine in 15 mL of tetrahydrofuran. The mixture was
allowed to reflux for one day and then extracted with 30 mL saturated sodium
bicarbonate solution. The aqueous layer was further extracted with 3 X 10 mL
chloroform. The chloroform was evaporated off and the crude product was
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recrystallized in ethyl acetate solution. The product was in the form of pale gold
crystals and weighed 0.090 g (0.2 mmol, 15.8 % yield). HPLC (method B) tR = 6.77
(96% Pure). ¹H NMR δ (ppm)(CHCl3-d): 1.30 (4 H, d, J = 10.45 Hz), 1.68 (5 H, s),
1.87 (2 H, s), 1.95 (4 H, dt, J = 10.86, 5.61 Hz), 2.34 (1 H, s), 2.61-2.67 (3 H, m), 2.76
(4 H, s), 3.38 (2 H, q, J = 5.14 Hz), 6.32 (1 H, d, J = 5.42 Hz), 7.30 (1 H, dd, J = 8.90,
2.19 Hz), 7.72 (1 H, s), 7.90 (1 H, d, J = 8.93 Hz), 7.94 (1 H, d, J = 2.16 Hz), 8.51 (1
H, d, J = 5.37 Hz). ¹³C NMR δ (ppm)(CHCl3-d): 23.3, 25.9, 26.3, 28.9, 44.5, 48.9,
54.1, 59.0, 63.6, 98.5, 117.7, 122.3, 124.6, 128.5, 134.7, 149.1, 150.8, 152.2. ESIMS
[M + H]+ calcd for C22H31ClN4 387.2310, found 387.2303.

Synthesis of PL255 N,N'-(3,3'-(piperazine-1,4-diyl)bis(propane-3,1diyl))diquinolin-4-amine
1.5 g (9.2 mmol) of 4-chloroquinoline was added to 0.87 g of (4.4 mmol)3,3'(piperazine-1,4-diyl)dipropan-1-amine and 6 g (63.8 mmol) of then heated at ~125oC
for 4 hrs( temperature and time control were critical as dark tarry by products formed
with large variations in time and temperature). The solution was allowed to cool to
room temperature and then diluted with 40 mL dichloromethane. The solution was
then washed with 6 X 20 mL 2 M sodium hydroxide and then 30 mL brine. The
resulting solution was dried over magnesium sulphate. After the solvent was
evaporated the solid product was recrystallized in ethyl acetate solution. 0.13 g (0.3
mmol, 6.6 % yield) of a white crystal powder was obtained. HPLC (method B) tR =
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4.73 (95% Pure). ¹H NMR δ (ppm)( CHCl3-d): 8.55 (2 H, d, J = 5.31 Hz), 7.98 (2 H,
dd, J = 8.47, 1.18 Hz), 7.94 (2 H, d, J = 8.38 Hz), 7.63 (2 H, ddd, J = 8.45, 6.83, 1.33
Hz), 7.41 (2 H, ddd, J = 8.38, 6.82, 1.28 Hz), 7.25 (2 H, s), 6.38 (2 H, d, J = 5.36 Hz),
3.44 (4 H, q, J = 5.29 Hz), 2.77-2.71 (12H, m), 2.07-1.99 (4 H, m). ESIMS [M + H]+
calcd for C28H34N6 382.1793, found 382.1784.

Synthesis of PL257 7-chloro-N-(3-(4-(4-nitrophenyl)piperazin-1yl)propyl)quinolin-4-amine

0.67 g (2.1 mmol) of PL29 was added to 0.53 g (2.6 mmol) of 1-(4nitrophenyl)piperazine and 0.43 g (4.3 mmol) of triethylamine in 15 mL of
tetrahydrofuran. The mixture was allowed to reflux for one day and then extracted
with 30 mL saturated sodium bicarbonate solution. The aqueous layer was further
extracted with 3 X 10 mL chloroform. The chloroform was evaporated off and the
crude product was recrystallized in ethyl acetate solution. The product was in the form
of bright yellow crystals and weighed 0.06 g (0.1 mmol, 6.6 % yield). HPLC (method
B) tR = 8.93 (95% Pure). ¹H NMR δ (ppm)(DMSO-d6): 211.41 (1 H, d, J = 5.40 Hz),
211.26 (1 H, d, J = 9.03 Hz), 211.11-211.03 (2 H, m), 210.79 (1 H, d, J = 2.25 Hz),
210.45 (1 H, dd, J = 8.97, 2.25 Hz), 210.39 (1 H, t, J = 5.29 Hz), 210.04 (2 H, d, J =
9.14 Hz), 209.52 (1 H, d, J = 5.48 Hz), 206.48 (4 H, t, J = 4.66 Hz), 205.50-205.43 (3
H, m), 204.92-204.81 (2 H, m), 203.01 (4 H, s).¹³C NMR δ (ppm)(CHCl3-d): 159.7,
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154.9, 141.4, 139.4, 132.7, 130.9, 129.3, 122.7, 108.4, 103.8, 96.7, 60.8, 58.6, 57.8,
51.6 , 46.7, 4.8. ESIMS [M + H]+ calcd for C22H24Cl1N5O2 426.1691, found 426.1682.

Synthesis of PL258 2-(3-(4-phenylpiperazin-1-yl)propyl)isoindoline-1,3-dione

6.00 g (37 mmol) of 1-phenylpiperazine was added to 9.44 g (35 mmol) of 2-(3bromopropyl)isoindoline-1,3-dione and 12.17 g (88 mmol) of potassium carbonate in
150 mL of acetonitrile. The mixture was allowed to reflux for 3 hrs. On cooling the
acetonitrile was evaporated off and the residue extracted with 200 mL water and 200
mL ethylacetate. The aqueous layer was extracted with 2 X 100 mL ethyl acetate and
combined to the organic layer. The solvent was evaporated off to give a pale yellow
liquid that solidified after being left in the fume hood. The product was recrystallized
in hexane to give a white powder 6.00 g (15 mmol, 43 % yield). ¹H NMR δ
(ppm)(CHCl3-d): 7.87-7.80 (2 H, m), 7.74-7.66 (2 H, m), 7.44 (2 H, d, J = 8.63 Hz),
6.84 (2 H, d, J = 8.61 Hz), 3.80 (2 H, t, J = 6.90 Hz), 3.13-3.08 (4 H, m), 2.55-2.44 (6
H, m), 1.90 (2 H, p, J = 6.85 Hz).

Synthesis of PL259 3-(4-phenylpiperazin-1-yl)propan-1-amine
6.00 g (15 mmol) of PL258 was dissolved in 75 mL of ethanol and 2.25 g (45 mmol)
of hydrazine monohydrate was added. The mixture was allowed to reflux for 4 hrs and
then the residue was evaporated off. The remaining solid was partitioned in
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chloroform and filtered off to get the amine a pale yellow solid 1.34 g (6.1 mmol, 41%
yield).

Synthesis of PL260 1-(3-phenylpropyl)-4-(4-(triflouromethyl)phenyl)piperazine

0.5 g (2.8 mmol) of 1-(4-(trifluoromethyl)phenyl)piperazine was added to 0.54 g (2.70
mmol) of (3-bromopropyl)benzene and 0.93 g (6.8 mmol) of potassium carbonate in
20 mL of acetonitrile. The mixture was allowed to reflux for 3 hrs. On cooling the
acetonitrile was evaporated off and the residue extracted with 20 mL water and 20 mL
ethyl acetate. The aqueous layer was extracted with 2 X 10 mL ethyl acetate and
combined to the organic layer. The solvent was evaporated off to give an off white
liquid that solidified after being left in the fume hood. The product was recrystallized
in hexane to give a white powder 0.51 g (1.7 mmol, 63.8 % yield). HPLC (method B)
tR = 15.88 (95% Pure). ¹H NMR δ (ppm)(400MHz, CHCl3-d): 7.47 (2 H, d, J = 8.63
Hz), 6.91 (2 H, d, J = 8.62 Hz), 3.30-3.25 (4 H, m), 2.67 (2 H, t, J = 7.71 Hz), 2.602.55 (4 H, m), 2.47-2.39 (2 H, m), 1.92-1.80 (2 H, m). ¹³C NMR δ (ppm)(CHCl3-d):
153.2, 141.9, 128, 128.1, 125.8, 125.2, 114.2, 57.6, 52.6, 48.2, 47.8, 33.7, 28.7.
ESIMS [M + H]+ calcd for C20H24F3N2 383.1741, found 383.1745
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Synthesis of PL261 7-chloro-N-(3-(4-(pyrimidin-2-yl)piperazin-1yl)propyl)quinolin-4-amine

0.3 g (1.0 mmol) of PL29 was added to 0.17 g (1.1 mmol) of 2-(piperazin-1yl)pyrimidine and 0.19 g (1.9 mmol) of triethylamine in 15 ml THF. The mixture was
allowed to reflux for one day and then extracted with 30 mL saturated sodium
bicarbonate solution. The aqueous layer was further extracted with 3 X 10 mL
chloroform. The chloroform was evaporated off and the crude product was columned
in 1:1 methanol:ethylacetate solution. The product was in the form of beige crystals
and weighed 0.16 g (0.4 mmol, 44 % yield). HPLC (method B) tR = 6.95 (99% Pure).
¹H NMR δ (ppm)(CH3OH-d4): 8.38 (1 H, d, J = 5.65 Hz), 8.34 (2 H, d, J = 4.78 Hz),
8.11 (1 H, d, J = 9.01 Hz), 7.80 (1 H, d, J = 2.17 Hz), 7.42 (1 H, dd, J = 9.01, 2.19 Hz),
6.64-6.56 (2 H, m), 3.85 (4 H, t, J = 4.99 Hz), 3.48 (2 H, t, J = 6.82 Hz), 2.62-2.56 (6
H, m), 2.01 (2 H, p, J = 7.01 Hz).¹³C NMR δ (ppm)(CHCl3-d): 26.2, 42.6, 44.7, 54.2,
57.5, 99.7, 111.3, 118.8, 124.3, 126.0, 127.6, 136.4, 149.7, 152.5, 152.8, 159.1, 162.9.
ESIMS [M + H]+ calcd for C20H24ClN6 383.1741, found 383.1745

Synthesis of PL272 N-(3-(4-phenylpiperazin-1-yl)propyl)acetamide
1.3 g (6.0 mmol) of the amine was treated with 0.9 g (12 mmol) of acetyl chloride in
30 mL acetonitrile. After 24 hrs the solvent was evaporated off and the solid dissolved
in 60 mL sodium bicarbonate solution. 3 X 20 mL of chloroform was used to extract
the product which was a beige powder 1.1 g (4.2 mmol, 28 %).
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HPLC (method B) tR = 7.71 (97% Pure).¹H NMR δ (ppm)(CH3OH-d4): 7.13 (2 H, dd,
J = 8.68, 7.20 Hz), 6.87 (2 H, d, J = 8.21 Hz), 6.74 (1 H, t, J = 7.31 Hz), 3.15 (6 H, m),
2.55 (4 H, t, J = 4.92 Hz), 2.36 (2 H, t, J = 7.65 Hz), 1.83 (3 H, s), 1.65 (2 H, t, J =
7.49 Hz). ¹³C NMR δ (ppm)(CH3OH-d4): 173.6, 153.5, 130.4, 121.5, 117.7, 57.7,
54.6, 50.6, 38.9, 27.2, 22.4. ESIMS [M + H]+ calcd for C15H24ON3 262.1914, found
262.1915.

Synthesis of PL289 3-chloro-N-(pyridin-4-yl)propanamide

12.43 mL (130 mmol) of chloropropionyl chloride was added dropwise to 10.34 g
(110 mmol) of 4-aminopyridine. 17.97 g (130 mmol) of potassium carbonate was used
as base in 130 mL dichloromethane. The reaction mixture was stirred at room
temperature for five days. The residue was evaporated off and the resulting white solid
was recrystallized in water. The product was a white powder 2.00 g (11 mmol, 10%).

Synthesis of PL273 3-(4-phenylpiperazin-1-yl)-N-(pyridin-4-yl)propanamide

1.33 g (7.2 mmol) of 3-chloro-N-(pyridin-4-yl)propanamide was added to 1.29 g (8.0
mmol) of 1-phenylpiperazine and 1.49 g (11 mmol) in 45 mL DMF. The mixture was
refluxed for 5 days. The residue was evaporated off and the solid was partitioned in 30
mL sodium bicarbonate solution. 3 X 15 mL of chloroform was used to extract the
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solution. The solid was obtained by recrystallization in ethanol as off white crystals
0.20 g (0.7 mmol, 9.4%). HPLC (method B) tR = 5.58 (95% Pure). ¹H NMR δ
(ppm)(CH3OH-d4): 8.40 (2 H, dd, J = 4.98, 1.64 Hz), 7.66 (2 H, dd, J = 4.97, 1.63
Hz), 7.25-7.24 (2 H, m), 7.00-6.97 (2 H, m), 6.86 (1 H, t, J = 7.31 Hz), 3.23 (4 H, t, J
= 4.88 Hz), 2.86 (2 H, t, J = 6.96 Hz), 2.74 (4 H, t, J = 4.90 Hz), 2.68 (2 H, t, J = 6.96
Hz). ¹³C NMR δ (ppm)(CH3OH-d4): 173.6, 152.6, 150.8, 148.0, 130.1, 121.2, 117.5,
115.1, 54.7, 54.0, 50.4, 35.0. ESIMS [M + H]+ calcd for C18H23ON4 311.1866, found
311.1868

Synthesis of PL274 7-chloro-N-(2-(4-phenylpiperazin-1-yl)ethyl)quinolin-4-amine

6 g (20 mmol) of sulphonyl adduct were treated with 3.56 g (22 mmol) of 1phenylpiperazine and 4.04 g (40 mmol) triethylamine in 50 mL acetonitrile. The
mixture was allowed to reflux for 48 hrs. The solvent was evaporated off and the
remaining solid was partitioned with 150 mL sodium bicarbonate solution. It was then
extracted with 50 X 3 mL of chloroform. The solid was columned on silica with a
50:50 methanol:ethylacetate mixture. The solid product was light brown 2 g (5.5
mmol, 27%). HPLC (method B) tR = 8.14 (98% Pure). PL274
(CH3OH-d4): 8.41 (1 H, d, J = 5.62 Hz), 8.11 (1 H, d, J = 9.01 Hz), 7.82 (1 H, d, J =
2.18 Hz), 7.45 (1 H, dd, J = 9.02, 2.19 Hz), 7.26-7.25 (2 H, m), 7.01-7.01 (2 H, m),
6.86 (1 H, t, J = 7.30 Hz), 6.62 (1 H, d, J = 5.66 Hz), 3.59 (2 H, t, J = 6.67 Hz), 3.25 (4
H, t, J = 4.86 Hz), 2.84 (2 H, t, J = 6.67 Hz), 2.78 (4 H, t, J = 4.88 Hz). ¹³C NMR δ
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(ppm)(CH3OH-d4): 40.8, 50.6, 54.2, 57.1, 99.8, 117.4, 121.3, 124.2, 126.2, 127.7,
128.4, 130.0, 131.6, 136.5, 149.8, 152.5, 161.4. ESIMS [M + H]+ calcd for
C21H24ClN4 367.1684, found 367.1679.

In vitro Inhibition of Growth Studies. The antimalarial activities of the synthesized
compounds were measured versus the CQ sensitive strain D6 and the CQ resistant
strains Dd2 and 7G8 using the standardized, malaria SYBR Green assay.95-97
Continuously maintained cultures of D6, Dd2, and 7G8 were used. The cultures were
diluted with complete medium (RPMI-1640 with 0.5 % Albumax II) to achieve 0.2 %
parasitemia and 2 % hematocrit. In 96-well micro plates, CQ (positive control) or the
respective compound was diluted in complete medium from a 10 mM stock in DMSO
which was added to the cell mixture to yield triplicate wells with drug concentrations
ranging from 0 to 10-4 M in a final well volume of 100 µL. After 72 h of incubation
under standard culture conditions, plates were harvested and read by the SYBR Green
I fluorescence-based method using a 96-well fluorescence plate reader (Gemini-EM,
Molecular Devices), with excitation and emission wavelengths at 497 and 520 nm,
respectively. The fluorescence readings were plotted against log [drug], and the IC50
values were obtained from curve fitting performed by nonlinear regression using
Prism (Graph Pad) software.
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Mouse Efficacy Against P. berghei.
Compounds were formulated in a solution consisting of 70% Tween-80 (d = 1.08
g/mL) and 30% ethanol (d = 0.81 g/mL), followed by a 10-fold dilution in water. On
day 0, heparinized blood (containing 100 µL of 200 u/mL Heparin) was taken from a
donor NMRI mouse with approximately 30% parasitemia. The blood was diluted in
physiological saline to 108 parasitized erythrocytes per mL. From this suspension 0.2
mL was injected intravenously (i.v.) into experimental groups of 3 female NMRI
mice, and a control group of 5 mice. Compounds were administered in a volume of
10ml/kg either as single dose 24 hours after infection (day 1) either by oral gavage
(p.o.) or subcutaneous injection, or as 4 consecutive daily p.o. doses 4, 24, 48 and 72
hours after infection (days 0-3). On day 3 (with the single-dose regimen) or on day 4
(with the quadruple-dose regimen), 1 µL tail blood was taken and dissolved in 1 mL
PBS buffer. Parasitemia was determined with a FACScan (Becton Dickinson) by
counting 100,000 RBCs. The difference between the mean value of the control group
and those of the experimental groups was calculated and expressed as a percent
relative to the control group (= activity). Animals receiving no compound would die
typically 5-6 days post-infection and were therefore euthanized right after
determination of parasitemia. The survival of the animals was monitored up to 30
days. Mice surviving for 30 days were checked for parasitemia and subsequently
euthanized. A compound was considered curative if the animal survived to 30 days
post-infection with no detectable parasites by microscopy, with a detection limit of 1
parasite in 10’000 erythrocytes (that is, 0.01%).
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APPENDIX A
Compound List
There is a 30% uncertainty in the IC50 values that may result from differences in
weighing and/or variations in determining IC50 as detailed in Chapter 7.
a

ClogP values were calculated using Chemdraw Ultra 12.0.

b

IC50 values were normalized to CQ values: D6: 6.9 nM, Dd2: 102 nM, 7G8: 106 nM.
Compound

a

Structure

HN

CQ
Cl

ClogP

N

5.1

b

IC50(nM)

6.9 D6
102 Dd2
106 7G8

N

PL154

6.6

PL156

6.0

PL157

5.7

PL158

6.9

PL159

5.0

PL257

5.8
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0.3 D6
0.5 Dd2
0.1 7G8
2.0 D6
0.2 Dd2
0.2 7G8
1.3 D6
0.3 Dd2
0.3 7G8
0.06 D6
0.2 Dd2
0.3 7G8
4.1 D6
4.1 Dd2
2.8 7G8
0.9 D6
0.8 Dd2
0.3 7G8

Compound

a

Structure

ClogP

b

IC50(nM)

0.1 D6
1.3 Dd2
0.5 7G8

PL163

6.2

PL112

7.0

1.2 D6
2.6 Dd2

PL111

7.0

0.9 D6
1.8 Dd2

PL110

7.0

PL274

0.7 D6
0.6 Dd2
0.2 7G8

0.5 D6
0.5 Dd2

5.2

PL91

4.1

HN

N

N

PL227

5.0
Cl

N

PL223

7.3
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0.5 D6
0.5 Dd2
0.5 7G8
2.4 D6
7.0 Dd2
9.0 7G8
0.5 D6
1.0 Dd2
1.2 7G8
1.1 D6
1.1 Dd2
0.8 7G8

Compound

a

Structure

ClogP
4.3

PL106

4.3

PL109

4.1

PL261

4.8

PL229

5.5

PL228

b

IC50(nM)

0.7 D6
1.1 Dd2
0.9 7G8
0.5 D6
1.6 Dd2
1.1 7G8
1.4 D6
2.3 Dd2
2.3 7G8
1.0 D6
2.0 Dd2
2.8 7G8
0.2 D6
0.4 Dd2
0.5 7G8
0.6 D6
0.02 Dd2
0.2 7G8

PL192

4.9 D6
9.8 Dd2
25 7G8

PL255

>2500 D6
>2500 Dd2
>2500 7G8

PL272

>2500 D6
>2500 Dd2
>2500 7G8

PL273

>2500 D6
>2500 Dd2
>2500 7G8

PL260
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APPENDIX B

Example of Spectra of PL91

All the proton and carbon spectra were run on a Bruker NMR at 400 MHz.

The sample was dissolved in MeOD, and TMS was used as the spectral reference.

Figure A.1 - Proton spectrum with integrals
Figure A.2 - 13C spectrum

Figure A.3 - COSY spectrum

Figure A.4 - NOESY spectrum

Figure A.5 - HMBC spectrum
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Figure A.1 Proton Spectra of PL91 with integrals. The aliphatic portion of the
spectrum is shown at the top and the aromatic portion is shown at the bottom.
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Figure A.2 13C spectrum.
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Figure A.3 COSY spectrum showing direct proton-proton interactions.
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Figure A.4 NOESY spectrum indicating though-space proton-proton
interactions.
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Figure A.5 HSQC spectrum indicating direct proton-carbon interactions.
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